BMJ Open

Head and neck cancer and occupational exposure to solvents in women: results from the ICARE study

Journal:	BMJ Open
Manuscript ID	bmjopen-2016-012833
Article Type:	Research
Date Submitted by the Author:	30-May-2016
Complete List of Authors:	Carton, Matthieu; INSERM, Epidemiologic Cohorts Unit ; University of Versailles St-Quentin, UMRS1018 , UMS 011 Barul, Christine; Inserm U 1085, Institut de Recherche Santé Environnement & Travail (IRSET) Menvielle, Gwenn; INSERM, Department of social epidemiology; Sorbonne University, Department of social epidemiology Cyr, Diane; INSERM, Epidemiologic Cohorts Unit – UMS 011 INSERM – UVSQ; University of Versailles St-Quentin, Sanchez, Marie; INSERM, CESP Centre for Research in Epidemiology and Population Health, Environmental epidemiology of cancer; University of Paris Sud 11, Pilorget, Corinne; Institut de Veille Sanitaire, Département Santé Travail; University Lyon 1, University Lyon, Unité mixte de recherche épidémiologique et de surveillance en transport, travail et environnement (Umrestte), F-69622, Umrestte Trétarre, Brigitte; Hérault Cancer Registry, Stücker, Isabelle; INSERM, CESP Centre for Research in Epidemiology and Population Health, Environmental epidemiology of cancer; University of Paris Sud 11, University Lyon 1, University Lyon, Unité mixte de recherche épidémiologique et de surveillance en transport, travail et environnement (Umrestte), F-69622, Umrestte Trétarre, Brigitte; Hérault Cancer Registry, Stücker, Isabelle; INSERM, CESP Centre for Research in Epidemiology and Population Health, Environmental epidemiology of cancer; University of Paris Sud 11, Luce, Danièle; INSERM , U 1085_IRSET ; University of Rennes 1,
Primary Subject Heading :	Occupational and environmental medicine
Secondary Subject Heading:	Oncology, Public health, Ear, nose and throat/otolaryngology, Epidemiology
Keywords:	head and neck, Cancer, trichloroethylene, perchloroethylene, occupational exposures, women

SCHOLARONE[™] Manuscripts

9	BMJ Open
	Title
	Head and neck cancer and occupational exposure to solvents in women: results from the ICARE study
	Running title
	Head and neck cancer and occupational exposure to solvents in women: results from the ICARE study
	Complete names, academic degrees and affiliations (to the department level) of all authors
	Matthieu Carton ^{1,2} , Christine Barul ⁸ , Gwenn Menvielle ⁹ , Diane Cyr ^{1,2} , Marie Sanchez ^{3,4} , Corinne Pilorget ^{5,6} ,
	Brigitte Trétarre ⁷ , Isabelle Stücker ^{3,4} , Danièle Luce ⁸ for the Icare Study Group [#] .
	¹ Inserm, Population-based Epidemiologic Cohorts Unit, UMS 011, Villejuif, France
	² University of Versailles St-Quentin, UMRS 1018, Villejuif, France
	³ Inserm, CESP Centre for research in Epidemiology and Population Health, UMRS 1018, Environmental
	epidemiology of cancer Team, Villejuif, France
	⁴ University Paris-Sud, UMRS 1018, Villejuif, France
	⁵ French institute for public health surveillance, Department of occupational health, Saint Maurice, France
	⁶ UMRESTTE (Epidemiological Research and Surveillance Unit in Transport, Occupation and Environment),
	University Claude Bernard, Lyon, France
	⁷ Hérault Cancer Registry, Montpellier, France
	⁸ Inserm U 1085 – Institut de Recherche Santé Environnement & Travail (IRSET), Faculté de Médecine, Pointe-
	à-Pitre, France
	⁹ Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), F75012, Paris, France
	# : Members of Icare Study Group
	Registre des cancers du Calvados, France (Anne-Valérie Guizard); Registre des cancers du Doubs, France
	(Arlette Danzon, Anne-Sophie Woronoff); Registre des cancers du Bas-Rhin, France (Velten Michel); Registre
	des cancers du Haut-Rhin, France (Antoine Buemi, Émilie Marrer) ; Registre des cancers de l'Hérault, France
	(Brigitte Tretarre) ; Registre des cancers de l'Isère, France (Marc Colonna, Patricia Delafosse) ; Registre des
	cancers de Loire-Atlantique-Vendée, France (Paolo Bercelli, Florence Molinie) ; Registre des cancers de la
	Manche, France (Simona Bara) ; Registre des cancers de la Somme, France (Benedicte Lapotre-Ledoux, Nicole
	Raverdy);
	Inserm, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology
	of cancer Team, Villejuif, France (Sylvie Cénée, Oumar Gaye, Florence Guida, Farida Lamkarkach, Loredana
	Radoï, Marie Sanchez, Isabelle Stücker);
	Inserm Epidemiologic Cohorts Unit - UMS 011 INSERM-UVSQ, Villejuif, France (Matthieu Carton, Diane Cyr,
	Annie Schmaus)
	University Lyon 1, UMRESTTE, Lyon, France: Joëlle Févotte
	French Institute for Public Health Surveillance, Department of Occupational Health, Saint Maurice, France:
	Corinne Pilorget
	Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique

Iblique CU Ί, (IPLESP UMRS 1136), Paris, France (Gwenn Menvielle)

Inserm U 1085 - IRSET, Pointe-à-Pitre, France (Danièle Luce)

Institution at which the work was performed

Inserm, CESP Centre for research in Epidemiology and Population Health, UMRS 1018

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Indication of and complete contact information (including email address) for the corresponding author Danièle Luce: daniele.luce@inserm.fr Inserm U 1085 - Irset Faculté de Médecine Campus de Fouillole BP 145 97154 Pointe-à-Pitre Téléphone : +33 (0)2 23 23 69 11 +33 (0)2 23 23 50 55 Télécopie :

A Conflict of Interest Statement (a short statement either disclosing conflicts or declaring that no conflicts exist) No conflicts exists

Contributors

MC and DL designed the current study, conducted the analyses and drafted the manuscript; CB, GM contributed to the statistical analysis and interpretation of the results. DC, CP, BT were involved in data collection, management and quality control. DL and IS are the principal investigators of the ICARE study, conceived this study and coordinated the original collection of the data. All the authors critically reviewed and revised the manuscript; and gave their approval for its final version.

Manuscript word count 4 850

BMJ Open

Title: Head and neck cancer and occupational exposure to solvents in women: results from the ICARE study

Abstract

Objective: Our objective was to investigate the association between head and neck cancer and occupational exposure to chlorinated, oxygenated and petroleum solvents in women. Methods: ICARE, a French population-based case-control study, included 296 squamous cell carcinomas of the head and neck (HNSCC) in women and 775 female controls. Lifelong occupational history was collected. Job-exposure matrices allowed to assess exposure to five chlorinated solvents (carbon tetrachloride; chloroform; methylene chloride; perchloroethylene; trichloroethylene), 5 petroleum solvents (benzene; special petroleum product; gasoline; white-spirits and other light aromatic mixtures; gasoil, fuels and kerosene) and 5 oxygenated solvents (alcohols; ketones and esters; ethylene glycol; diethyl ether; tetrahydrofuran). Odds ratio (ORs) and 95% confidence intervals (CI), adjusted for smoking, alcohol drinking, age and department, were estimated with logistic models. Results: Elevated ORs were observed among women ever exposed to perchloroethylene (OR=2.97, 95%CI: 1.05-8.45) and trichloroethylene (OR=2.15, 95%CI: 1.21-3.81), which increased with exposure duration- (respectively OR=3.75, 95%CI: 0.64-21.9 and OR=4.44, 95%CI: 1.56-12.6 for ten years or more). No significantly increased risk of HNSCC was found for occupational exposure to the other chlorinated, petroleum or oxygenated solvents. *Conclusions*: These findings suggest that exposure to perchloroethylene or trichloroethylene may increase the risk of HNSCC in women. In our study, there is no clear evidence that other studied solvents are risk factors for HNSCC.

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Keywords: head and neck; cancer; trichloroethylene; perchloroethylene; occupational exposures; women; solvents

Strengths and limitations

Little is known about occupational risk factors for head and neck cancer in women. Our study is one of the largest studies on this topic.

The study was population based; exposure to solvents was assessed from the entire occupational history, obtained from in-person interviews.

Special attention was paid to adjustment for alcohol and tobacco consumption

Exposure assessment through job-exposure matrices may entail misclassification of exposure, which is likely to be nondifferential.

Despite a relatively large number of cases, statistical power was limited for in-depth analyses by cancer sites.

Data sharing statement: No additional data are available.

Introduction

Compared to other European Union countries, head and neck cancers (HNC) are frequent in France [1]. The world standardized cancer incidence rates in 2012 in France are greater than 16 per 100,000 for lip, oral cavity and pharynx (LOCP) cancers and 5.4 per 100,000 for laryngeal cancer in men, and greater than 5 per 100,000 for LOCP and 0.9 per 100,000 for laryngeal cancer in women. Moreover, in 1980–2012, the incidence of LOCP cancer and laryngeal cancer increased by 60% and 50%, respectively, in women, while it decreased by 60% and 62%, respectively, in men [2].

Tobacco smoking and alcohol consumption are well established major risk factors for these cancers [3], and the joint effect of tobacco and alcohol is at least multiplicative [4].

In addition to these major risk factors, several studies have investigated the role of occupational exposures in the occurrence of head and neck cancers. Thus, some occupations in men [5-17] and women [14, 18-21] were associated with the risk of developing head and neck cancer.

In a previous analysis by occupation among women [22], we found a high risk of head and neck cancer associated with various occupations and industries, among them electrical and electronic equipment assemblers, radio, television and communication equipment manufacturing, flame cutters, welders and printers, which suggested a possible role of exposure to solvents. Some studies have shown an increased risk of HNC associated with exposure to solvents [23, 24]. Some solvents such as trichloroethylene [25], perchloroethylene [25] or benzene [26] are classified as proven or probable carcinogens by IARC, but for cancer sites other than head and neck.

The majority of results on the association between solvent exposures and cancers of the upper aerodigestive tract were observed in studies conducted in men and very few studies BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

were conducted among women. However, chlorinated and oxygenated solvents are commonly used by women [27]. In addition, circumstances of exposure can vary between men and women and some studies have suggested gender differences in the toxicokinetics of solvents [28, 29]. ICARE (Investigation of occupational and environmental CAuses of .ge Lunity to st. Lexposures to chlor. REspiratory cancers), one of the largest population-based case-control studies of head and neck cancer, offers the opportunity to study the association between cancer of the head and neck and occupational exposures to chlorinated, oxygenated and petroleum solvents in women.

Study population

ICARE has been described in detail previously [30]. Briefly, ICARE is a multi-center, population-based case-control study, which included a group of 2926 lung cancer cases, a group of 2415 head and neck cancer cases, and a common control group of 3555 subjects. Incident cases were identified in collaboration with cancer registries in 10 geographical areas in France. All incident primary cancer cases of the head and neck diagnosed between 2001 and 2007 were included, comprising malignant neoplasms of the lip, oral cavity and pharynx (C00-C14), nasal cavity and accessory sinuses (C30.0, C31) and larynx (C32) as coded by the International Classification of Diseases for Oncology, third edition (ICD-O-3). Included cases were histologically confirmed cases, aged 18 years to 75 years at diagnosis. All histological types were included. The control group was a random sample of the population of the same geographical areas, with a distribution by sex and age comparable to that of both head and neck cancer and lung cancer cases, and a distribution by socioeconomic status comparable to that of the general population. Subjects were interviewed face to face, using a standardized questionnaire collecting information on lifetime tobacco and alcohol consumption, residential history, and a detailed description of occupational history. Participation rates were 80.6% among controls and 82.5% among cases [30]. Each subject gave written informed consent. The study was approved by the Institutional Review Board of the French National Institute of Health and Medical Research (IRB-Inserm,

Study sample

n° 01-036), and by the French Data Protection Authority (CNIL n° 90120).

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Only women were considered in this analysis. In all, 361 female head and neck cancer cases were included in the ICARE study. The present analysis was restricted to squamous cell carcinomas of the following cancer sites: i) oral cavity, 88 cases (29.7%): codes C00.3 – C00.9, C02.0 – C02.3, C03.0, C03.1, C03.9, C04.0, C04.1, C04.8, C04.9, C05.0, C06.0–C06.2, C06.8, and C06.9; ii) oropharynx, 111 cases (37.5%): codes C01.9, C02.4, C05.1, C05.2, C09.0, C09.1, C09.8, C09.9, C10.0–C10.4, C10.8, and C10.9; iii) hypopharynx, 28 cases (9.5%): codes C12.9, C13.0 – C13.2, C13.8, and C13.9; iv) oral cavity, pharynx unspecified or overlapping, 22 cases (7.4%): codes C02.8, C02.9, C05.8, C05.9, C14.0, C14.2, and C14.8; v) larynx, 47 cases (15.9%): codes C32.0 – C32.3 and C32.8 – C32.9. There were 296 cases and 775 controls in the final study group.

Coding of job titles

Each job held for at least one month was coded using the International Standard Classification of Occupations (ISCO) [31] and the Nomenclature des Activités Françaises (NAF) [32], the French classification for industrial activities. Occupational histories were coded by specially trained coders blind as to the case-control status.

BMJ Open

Exposure assessment

Occupational exposure to five chlorinated solvents (carbon tetrachloride; chloroform; methylene chloride; perchloroethylene; trichloroethylene), 5 petroleum solvents (benzene; special petroleum product; gasoline; white-spirits and other light aromatic mixtures; gasoil, fuels and kerosene) and 5 oxygenated solvents (alcohols; ketones and esters; ethylene glycol; diethyl ether; tetrahydrofuran) was assessed using job-exposure matrices (JEMs) developed for the French population by the French Institute of Health Surveillance [33]. For each combination of ISCO and NAF codes, JEM assigned three indices of exposure: (*i*) a probability of exposure expressed as the percentage of exposed workers (*ii*) an intensity of exposure and (*iii*) a frequency of exposure.

Probability of exposure was categorized into <1, 1–10, 11–20, 21–30, 31–40, 41–50, 51–60, 61–70, 71–80, 81–90, or up to 91–100% for chlorinated and oxygenated solvents and into <1, 1–10, 11–50, 50–90 or up to 91–100% for petroleum solvents.

Intensity of exposure was categorized into (*i*) <5, 5–25, 26–50, 51–100, >100 ppm for trichloroethylene, perchloroethylene, and methylene chloride; (*ii*) <0.1, 0.1–1, 1–5, 5–15, >15 ppm for benzene; (*iii*) <1, 1–20, 20–50, >50 ppm for white-spirits (WS); (*iv*) <1, 1–50, 50–150, >150 ppm for gasoline; (*v*) not exposed, very low, low, medium and high for carbon tetrachloride, chloroform, ketones and esters and alcohols; (*vi*) not exposed, low, medium and high for special petroleum product, gasoil-fuel and kerosene, ethylene glycol, tetrahydrofuran and diethyl ether.

Frequency of exposure was categorized into (*i*) <1, 1–10, 11–20, 21–30, 31–40, 41–50, 51–60, 61–70, 71–80, 81–90 or up to 91–100% of working time for chlorinated and oxygenated solvents; (*ii*) <0.5, 0.5–5, 5–30, 30–70, up to 71–100% of working time for petroleum solvents.

To account for changes in exposure over time, indices were provided for different calendar periods from 1947 to 2007. Exposure information for 1947 was used for jobs held before this date.

In all analyses, 'never exposed' refers to subjects never exposed to a specific solvent and was used as the reference category. 'Ever exposed' to a specific solvent refers to subjects having had at least one job with probability of exposure greater than zero. Cumulative duration of exposure was computed by summing all exposed periods and used as a continuous variable as well as a dichotomized, binary variable (cutpoint: 10 years). Cumulative Exposure Indices (CEIs) were obtained by summing the product of exposure probability, frequency, intensity and duration for each job period, over the lifetime occupational history, using the central value of the classes. The CEIs were used as continuous variables as well as transformed into binary variables according to the median of the distributions among controls.

Statistical analysis

Unconditional logistic regression was used to estimate odds ratios (ORs) and corresponding 95% confidence intervals (95% CI) of head and neck cancers. Analyses were adjusted for geographic area (ten "départements"), age, smoking status (never smoker, former smoker and current smoker), tobacco consumption in pack-years, and alcohol consumption in drinkyears. Cubic splines were used for alcohol and tobacco because they allowed to better take into account their effects, according to the Bayesian information criterion. Since interactions between smoking status and alcohol consumption, and between smoking status and tobacco consumption, were significant, all models included these interaction terms.

Additional adjustments were made for socioeconomic status (SES) assessed by the last occupation and by the longest held occupation. Since additional adjustment for SES did not markedly change the results while it increased the number of parameters to be estimated, the odds ratios reported in the results section are those not adjusted for SES. Adjustment for asbestos exposure, was also performed; as was the case for SES, no significant effect was observed and these results are not presented here.

ORs were also estimated for each cancer site (as described upper: oral cavity, oropharynx, hypopharynx and larynx) using polytomous logistic regression.

Statistical analyses were performed using STATA software (StataCorp LP 2015; V. 13.1). All p values were two-sided and a p value ≤0.05 was used as a threshold for statistical significance.

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Results

The main characteristics of cases and controls are presented in Table I. On average, cases were 2 years younger than controls. This is explained by the fact that controls were stratified on age (in four categories: less than 40 years, 40-54 years, 55-64 years and >65 years) based on the age distribution of both head and neck cancer cases and lung cancer cases. The socioeconomic status of cases was lower than that of controls. Cases were less likely to be never smokers or never drinkers than controls.

Table II shows the association between head and neck cancers and ever exposed to chlorinated, petroleum and oxygenated solvents. The number of women ever exposed to chloroform (5 cases, 10 controls), carbon tetrachloride (6 cases, 12 controls), motors gasoline (4 cases, 9 controls), ethylene glycol (1 case, 5 controls) and tetrahydrofuran (4 cases, 3 controls) was very low; for this reason, these five solvents were excluded from further analyzes.

Ever exposure to trichloroethylene was associated with an increased risk of head and neck cancer (OR=2.15, 95% CI 1.21 to 3.81) and the risk increased with duration of exposure (OR=1.67, 95% CI 0.86 to 3.24 for less than 10 years and OR=4.44, 95% CI 1.56 to 12.6 for 10 years or more). Similar results were found for exposure to perchloroethylene, with an OR of 2.97 (95% CI 1.05 to 8.45) for ever exposure and an increase in risk with duration of exposure (OR=2.66, 95% CI 0.75 to 9.40 for less than 10 years and OR=3.75, 95% CI 0.64 to 21.9 for 10 years or more). On the other hand, no relationship was observed between head and neck cancer and cumulative exposure to trichloroethylene or perchloroethylene, the highest ORs being observed in the lowest cumulative exposure category. However, when duration or CEI was considered as a continuous variable, the relationship between head and

BMJ Open

neck cancer and CEI to trichloroethylene was significant (OR for elevation of 1 unit of CEI=1.02, 95% CI 1.01 to 1.04).

The study of the association between head and neck cancer and exposure to petroleum solvents showed slight, non significant elevations in risk for benzene (OR=1.65, 95% CI 0.87 to 3.13), gasoil (OR=1.79, 95% CI 0.75 to 4.29) and special petroleum product (OR=1.40, 95% CI 0.74 to 2.65). No dose-response relationship was found with the duration of exposure or with CEI.

With regards to oxygenated solvents, no elevated risks were associated with diethyl ether (OR=0.65, 95% CI 0.36 to 1.19) or alcohols (OR=0.83, 95% CI 0.57 to 1.20) exposure. A borderline significant elevated OR (OR=1.61, 95% CI 0.96 to 2.70) was associated with ketones exposure but without dose-response relationship with CEI (OR=2.27, 95% CI 1.16 to 4.44 for less than median and OR=1.10, 95% CI 0.52 to 2.31 for median or more) or duration of exposure.

The distribution of job periods exposed to trichloroethylene by occupation (See Supplementary material: Figure 1) shows that the most frequent occupations were shoes and leather workers, dry cleaners and launderers, rubber and plastics workers, welders and electronics workers. The most frequent sector of activity exposed to trichloroethylene was the leather and footwear industry.

Since leather workers are also exposed to benzene, we also estimated mutually adjusted ORs for the association between head and neck cancer and exposure to trichloroethylene and benzene. The OR for trichloroethylene remained significantly elevated (OR=2.05, 95% CI 1.04 to 4.01) whereas no association with benzene exposure was found (OR=1.11, 95% CI 0.52 to 2.36)

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

The distribution of job periods exposed to perchloroethylene by occupation (See Supplementary material: Figure 2) shows that the most frequent occupations were dry cleaners launderers, degreasers, assemblers in electrical and electronic equipment. The most frequent sector of activity was laundry and dry cleaning.

Exposures to trichloroethylene and perchloroethylene were strongly correlated, and were also correlated to methylene chloride exposure, which makes the interpretation of mutually adjusted ORs difficult. Instead, we studied exposure to exclusive combinations of chlorinated solvents (Table III). No cases were exposed only to perchloroethylene. The odds ratio associated with trichloroethylene alone is high (OR=1.81, 95% CI 0.81 to 4.04), but lower than in the analysis reported in Table II (OR=2.15, 95% CI 1.21 to 3.81). Exposure to methylene chloride alone is associated with an OR lower than 1 (OR=0.50, 95% CI 0.11 to 2.18). A high OR was associated with the joint exposure to trichloroethylene and perchloroethylene (OR=4.47, 95% CI 1.27 to 15.8).

Analyses by cancer sites are presented in Table IV. The OR associated with trichloroethylene exposure was higher for larynx (OR=3.80, 95%CI 1.55 to 9.32) and oral cavity (OR=2.12, 95%CI 0.97 to 4.60), the latter showing a dose-response relation with duration and cumulative exposure (See Supplementary material: Table S-I, OR=6.84, 95%CI 2.11 to 22.1 for duration > 10 years; OR=2.73, 95%CI 1.02 to 7.30 for CEI > median). Perchloroethylene exposure was associated with an increased risk of laryngeal (OR=7.95, 95%CI 1.92 to 32.9) and oropharyngeal cancers (OR=3.43, 95%CI 1.01 to 11.8), with no clear indication of dose-response relationships. The OR associated with ever exposure to ketones was significantly elevated for laryngeal cancer (OR=2.66, 95% CI 1.17 to 6.07) but there was no increase in risk with duration of exposure or CEI (See Supplementary materiel: Table S-III). Exposure to white-spirit (See Supplementary materiel: Table S-II) was associated with a non-significantly

BMJ Open

increased risk of oral cavity cancer (OR=1.54, 95% CI 0.90 to 2.66), which increased with CEI (OR=1.20, 95% CI 0.56 to 2.54 for CEI < median; OR=1.75, 95% CI 0.91 to 3.37 for CEI > median) and duration of exposure (OR=0.97, 95% CI 0.48 to 1.96 for < 10 years; OR=2.51, 95% CI 1.25 to 5.02 for 10 years or more).

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

This analysis studied occupational exposures to chlorinated, petroleum and oxygenated solvents in relation to head and neck cancer risk in women in France. Some solvent exposures associated with an increased risk of cancer in women have been identified. This is the case for exposure to trichloroethylene or perchloroethylene, with high and significant risks and with a duration-response relationship. Risks associated with other solvents were sometimes slightly elevated but not significantly so, or without duration-response relationships.

Trichloroethylene (TCE) is one of the most used chlorinated solvents. It has been used as a metal degreasing product and was also widely used for manually degreasing textiles, or cleaning machinery and equipment while applying paints, glues, adhesives, plastics, rubbers, etc. TCE was recently classified as carcinogenic to humans (Group 1) based on sufficient epidemiological evidence for cancer of the kidney. Most of the information on the association between TCE and cancer risk derives from cohort studies which include only a small number of head and neck cancers, especially among women, and sometimes do not report results for these cancer sites. Wartenberg et coll [34] reviewed data on exposure to TCE and cancer in a meta-analysis. They concluded that there was a weak suggestion of an increased risk of laryngeal cancer, and on average no evidence of an association with oral and pharyngeal cancer, despite substantial heterogeneity between studies. More recently, Raaschou-Nielsen [35] found SIRs of 1.8 for buccal cavity and pharynx cancers (10 observed) and 1.7 for larynx cancers (3 observed) in women exposed to TCE in a Danish cohort study including more than 340 companies with documented use of TCE. Interestingly, the SIRs among men were lower, around 1.1 to 1.2. Boice et coll. [36] reported a SMR of 1.25 for buccal cavity and pharynx cancers (4 observed) and 1.45 for larynx cancers (2 observed) Page 17 of 39

BMJ Open

among men exposed to TCE in a rocket engine testing facility. In 2013, Hansen et coll. [37] established a pooled cohort including 5553 workers with well documented individual exposure to TCE in Finland, Sweden and Denmark. They observed a SIR of 1.71 (95% CI 0.74 to 3.38) and 2.94 (95% CI 0.36 to 10.6) for buccal and pharyngeal cancers among men (8 observed) and women (2 observed) respectively. For laryngeal cancers, SIR was 1.46 (95% CI 0.72 to 2.61) in men (11 observed) and no case was observed in women. In a cohort of aircraft maintenance workers [38] a non-significantly increased risk of oral and pharyngeal cancer was observed for workers exposed vs not exposed to TCE among men (11 exposed cases, OR=1.23, 95% CI 0.34 to 4.43) and among women (2 exposed cases, OR=1.08, 95% CI 0.18 to 6.47), but no gradient with cumulative exposure was apparent. Overall, several studies of workers exposed to TCE have reported elevated but not statistically significant relative risks for oral, pharyngeal and/or laryngeal cancer, but the small number of cases and the lack of data on confounding factors make interpretation difficult. Our finding of a significantly increased risk of head and neck cancer associated with TCE exposure, based on a case-control study with larger numbers of exposed cases and with thorough adjustment for alcohol and tobacco consumption is globally consistent with the literature. We also observed a duration-response relationship. Concerning cumulative exposure, our results are less conclusive, with similar ORs below and above the median, but a globally significant trend with CEI. The increase in risk associated with TCE was higher for laryngeal cancer (OR=3.80, 95% CI 1.55 to 9.32), and to a lesser extent for cancer of the oral cavity (OR=2.12, 95% CI 0.97 to 4.60). However, a clear dose-response gradient with duration and cumulative exposure was apparent for oral cancer (OR 1.16 to 6.84 for less vs more than 10 years of exposure and 1.38 to 2.73 for less vs more than the median CEI), whereas similarly high ORs were observed in all categories of duration and cumulative exposure for laryngeal cancer.

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Since the 1950s, perchloroethylene (PCE), another widely used chlorinated solvent, was used extensively in dry cleaning but also for metal degreasing and for cleaning machinery and equipment. IARC classified PCE as probably carcinogenic to humans [25]. Since the 1990's, its use has been more limited, particularly for metal degreasing, but it remains effective for dry degreasing of clothes albeit under stricter conditions. The literature on the risks of head and neck cancers related to exposure to PCE is very limited. Mundt et coll. [39] reviewed the risk of cancer linked to PCE exposure. They concluded that the possibility of an association between oral, pharyngeal and laryngeal cancer and PCE appeared unlikely. In a cohort of dry cleaners, a significantly elevated SMR was observed for laryngeal cancer among workers with the highest estimated level of exposure to dry cleaning solvents, primarily PCE [40]. Deaths from cancer of the buccal cavity and pharynx were not in excess in this cohort. In another cohort of dry cleaners, exposure to PCE was found to be associated with a significant increase in tongue cancer, but not with laryngeal cancer [41]. As for TCE, these findings rely on small numbers of cases, and information on confounding factors was not available. A case-control study showed a high, although not significant, OR associated with exposure to PCE, after adjustment for alcohol and tobacco consumption [42]. In another case-control study, in which smoking and alcohol drinking were controlled for, a significantly increased risk of laryngeal cancer was also found to be associated with exposure to chlorinated solvents, but information on specific solvents was not available [24]. In line with these results, we observed elevated ORs for laryngeal cancers in relation with PCE (4 exposed cases, OR=7.95, 95% CI 1.92 to 32.9). However, we did not find any dose-response relationship, the highest ORs being observed in the lowest duration and CEI categories.

BMJ Open

In our study, it is not possible to distinguish precisely the risks associated to TCE and to PCE. Indeed, none of these women was exposed only to PCE. However, the study of combinations of exposures to different chlorinated solvents suggests that the risk for joint exposure to TCE and PCE (9 exposed cases, OR=4.47, 95% CI 1.27 to 15.8) is higher than for exposure to only TCE (20 exposed cases, OR=1.81, 95% CI 0.81 to 4.04).

In all, our results are consistent with an effect of occupational exposure to these two chlorinated solvents on the occurrence of head and neck cancers, particularly with laryngeal cancer. Among men in the ICARE study [43], there was also an increased risk of laryngeal cancer associated with high levels of exposure to PCE. However, no association was found between head and neck cancer and exposure to TCE in men, after adjustment for asbestos exposure. This difference in results between men and women is probably due to confounding by asbestos. In women, jobs involving exposure to TCE, mainly related to leather work or dry cleaning, are unlikely to entail exposure to asbestos, and actually adjusting for asbestos had no or very limited effect on the risk related to TCE in women. In men, the stronger correlation between asbestos and TCE exposure made it difficult to study an independent role of TCE. Another possible explanation is that there are true gender differences in risk. Some studies, although based on very small numbers, have suggested higher relative risks in women than in men, and gender differences in the toxicokinetics of TCE have been reported [28, 29, 44].

Petroleum solvents, and even more so oxygenated solvents, are also widely used by women in the workplace. Overall, our results do not provide evidence of a substantial role of these solvents in head and neck cancer etiology. However, we found a significantly increased risk of cancer of the oral cavity among women exposed for more than 10 years to white spirits, as well as a significantly increased risk of laryngeal cancer associated with exposure to BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

 ketones. To our knowledge, these associations have not be examined previously. Although these findings may be due to chance, they warrant further investigation.

One strength of our study is that it included almost 300 female incident cases of well characterized HNSCC. This makes it one of the largest case-control studies in women. The design of ICARE was population-based; cases were incident and were identified by qualified cancer registries in 10 French geographical areas. It was verified that the distribution of the main occupational and economic activity characteristics of the active population in these regions was similar to their distribution in France [30]. Participation rates were satisfactory for a population-based case-control study [30]. The control group was a random sample of the population of these areas and the distribution of socioeconomic characteristics was also similar to their distribution in the general population. Moreover, lifelong exposure prevalences among women controls were on the same order of magnitude to that estimated among women in the general population for the solvents under study [33]. Distribution by age, sex and cancer site of the head and neck cancer cases included in ICARE was similar to that observed for head and neck cancer cases in all of France. Thus, selection bias is unlikely, and was probably marginal if it occurred at all.

Our study has some limitations. Since this is a case-control study, recall bias is possible. However, it should be very limited since the number of jobs reported by cases and controls was similar (on average 3.3 for cases and 3.7 for controls). Although occupations and industries are self-reported, it is unlikely that this bias would be differential between cases and controls because occupational exposures are not widely known to be risk factors for head and neck cancers, particularly in women. Coding occupation and industry is difficult and often not reproducible. However, coders received special training and were blind as to case-control status. If coding errors were made, they were therefore not differential.

Residual confounding is always a possibility. But we took into account age, alcohol and tobacco, the interaction between alcohol and tobacco and socioeconomic status.

Special attention was paid to adjustment for alcohol and tobacco consumption, with the use of cubic splines allowing to better account for the effect of these two confounding factors. Therefore, residual confounding in relation with alcohol and tobacco consumption is unlikely to be a major problem in this study. However, other known or suspected risk factors such as nutritional factors or HPV infection were not considered in this analysis but it is unlikely that they explain the risks identified.

Another possible limitation of our study is that this type of JEM-analysis, based on jobspecific averages, do not achieve a high level of accuracy in the exposure assessment [45]. This procedure can produce misclassifications resulting in an estimation of the odds ratio biased towards 1, with an associated loss of statistical power [46]. However, this type of bias cannot explain positive findings.

Conclusion

In conclusion, our findings suggest that the exposure to TCE and PCE may be a risk factor for HNSCC in women; in contrast, there is no clear evidence that the other solvents studied are risk factors for HNSCC. Nevertheless, further investigations are necessary to replicate these results in a larger, exposed female population.

Acknowledgements

The ICARE study was funded by the French National Research Agency (ANR); French National Cancer Institute (INCA); French Agency for Food, Environmental and Occupational Health and Safety (ANSES); French Institute for Public Health Surveillance (InVS); Fondation pour la Recherche Médicale (FRM); Fondation de France; Association pour la Recherche sur le Cancer (ARC); Ministry of Labour (Direction Générale du Travail); Ministry of Health (Direction Générale de la Santé).

The present work was supported by a grant from the "Fondation ARC pour la recherche sur le cancer".

1 2 3 4		
5		Reference List
6 7		
8		
9		
10		
11	1	Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in
12		Europe in 2008. <i>Eur J Cancer</i> 2010; 46 (4):765-81.
13		
14	2	Binder-Foucard F, Bossard N, Delafosse P, et al. Cancer incidence and mortality in France over
15		the 1980-2012 period: solid tumors. <i>Rev Epidemiol Sante Publique</i> 2014; 62 (2):95-108.
16 17		
17 18	3	Secretan B, Straif K, Baan R, et al. A review of human carcinogensPart E: tobacco, areca nut,
19		alcohol, coal smoke, and salted fish. <i>Lancet Oncol</i> 2009; 10 (11):1033-4.
20		
21	4	Hashibe M, Brennan P, Chuang SC, et al. Interaction between tobacco and alcohol use and the
22		risk of head and neck cancer: pooled analysis in the International Head and Neck
23		Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009;18 (2):541-
24		50.
25		
26	5	Boffetta P, Gridley G, Gustavsson P, et al. Employment as butcher and cancer risk in a record-
27		linkage study from Sweden. Cancer Causes Control 2000;11 (7):627-33.
28		
29	6	Boffetta P, Richiardi L, Berrino F, et al. Occupation and larynx and hypopharynx cancer: an
30		international case-control study in France, Italy, Spain, and Switzerland. Cancer Causes
31		Control 2003; 14 (3):203-12.
32 33		
34	7	Brown LM, Mason TJ, Pickle LW, et al. Occupational risk factors for laryngeal cancer on the
35		Texas Gulf Coast. <i>Cancer Res</i> 1988; 48 (7):1960-4.
36		
37	8	De Stefani E, Boffetta P, Oreggia F, et al. Occupation and the risk of laryngeal cancer in
38		Uruguay. Am J Ind Med 1998; 33 (6):537-42.
39	0	Distr A. Descriptional Likeway T. et al. Evenes we to convert dust indicted accurational second
40	9	Dietz A, Ramroth H, Urban T, et al. Exposure to cement dust, related occupational groups and
41		laryngeal cancer risk: results of a population based case-control study. Int J Cancer
42		2004; 108 (6):907-11.
43	10	Coldborg D. Loclors A. Luco D. et al. Langaged and hypophanymetric concertant accuration:
44	10	Goldberg P, Leclerc A, Luce D, et al. Laryngeal and hypopharyngeal cancer and occupation:
45		results of a case control-study. <i>Occup Environ Med</i> 1997; 54 (7):477-82.
46 47	11	Merletti F, Boffetta P, Ferro G, et al. Occupation and cancer of the oral cavity or oropharynx in
47 48	11	Turin, Italy. Scand J Work Environ Health 1991; 17 (4):248-54.
40		Tulin, italy. Scullu 5 Work Environ Health 1991, 17 (4).246-34.
50	12	Muscat JE, Wynder EL. Tobacco, alcohol, asbestos, and occupational risk factors for laryngeal
51	12	cancer. <i>Cancer</i> 1992; 69 (9):2244-51.
52		cancer. cuncer 1552,05 (5).2244 51.
53	13	Paget-Bailly S, Guida F, Carton M, et al. Occupation and Head and Neck Cancer Risk in Men:
54	10	Results From the ICARE Study, a French Population-Based Case-Control Study. J Occup
55		Environ Med 2013.
56		
57		
58		
59 60		23
00		23

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

2	
3	
Δ	
5	
$\begin{array}{c} 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 43\\ 56\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 37\\ 38\\ 36\\ 36\\ 37\\ 38\\ 36\\ 36\\ 37\\ 38\\ 36\\ 36\\ 36\\ 37\\ 38\\ 36\\ 36\\ 36\\ 36\\ 36\\ 36\\ 36\\ 36\\ 36\\ 36$	
6	
7	
8	
9	
10	
11	
11	
12	
13	
14	
15	
16	
17	
11	
18	
19	
20	
21	
22	
22	
20	
24	
25	
26	
27	
28	
20	
29	
30	
31	
32	
33	
34	
35	
26	
30	
37	
38	
39	
40	
41	
42	
42	
-	
44	
45	
46	
47	
48	
40	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

- 14 Richiardi L, Corbin M, Marron M, *et al.* Occupation and risk of upper aerodigestive tract cancer: the ARCAGE study. *Int J Cancer* 2012;**130** (10):2397-406.
- 15 Schildt EB, Eriksson M, Hardell L, *et al.* Occupational exposures as risk factors for oral cancer evaluated in a Swedish case-control study. *Oncol Rep* 1999;**6** (2):317-20.
- 16 Wortley P, Vaughan TL, Davis S, et al. A case-control study of occupational risk factors for laryngeal cancer. Br J Ind Med 1992;49 (12):837-44.
- 17 Zagraniski RT, Kelsey JL, Walter SD. Occupational risk factors for laryngeal carcinoma: Connecticut, 1975-1980. *Am J Epidemiol* 1986;**124** (1):67-76.
- 18 Czene K, Tiikkaja S, Hemminki K. Cancer risks in hairdressers: assessment of carcinogenicity of hair dyes and gels. *Int J Cancer* 2003;**105** (1):108-12.
- 19 Huebner WW, Schoenberg JB, Kelsey JL, *et al.* Oral and pharyngeal cancer and occupation: a case-control study. *Epidemiology* 1992;**3** (4):300-9.
- 20 Ji J, Hemminki K. Occupation and upper aerodigestive tract cancers: a follow-up study in Sweden. *J Occup Environ Med* 2005;**47** (8):785-95.
- 21 Pukkala E, Martinsen JI, Lynge E, *et al.* Occupation and cancer follow-up of 15 million people in five Nordic countries. *Acta Oncol* 2009;**48** (5):646-790.
- 22 Carton M, Guida F, Paget-Bailly S, *et al.* Occupation and head and neck cancer in women-Results of the ICARE study. *Am J Ind Med* 2014;**57** (12):1386-97.
- 23 Berrino F, Richiardi L, Boffetta P, et al. Occupation and larynx and hypopharynx cancer: a jobexposure matrix approach in an international case-control study in France, Italy, Spain and Switzerland. Cancer Causes Control 2003;14 (3):213-23.
- 24 Shangina O, Brennan P, Szeszenia-Dabrowska N, et al. Occupational exposure and laryngeal and hypopharyngeal cancer risk in central and eastern Europe. Am J Epidemiol 2006;**164** (4):367-75.
- 25 IARC. TRICHLOROETHYLENE, TETRACHLOROETHYLENE, AND SOME OTHER CHLORINATED AGENTS. *IARC Monogr Eval Carcinog Risks Hum* 2014;**106**:1-512.
- 26 Cogliano VJ, Baan R, Straif K. Updating IARC's carcinogenicity assessment of benzene. Am J Ind Med 2011;54 (2):165-7.
- 27 Dananché B. Présentation de matrices emplois-expositions à cinq solvants chlorés. Quelques applications à un échantillon de population en France. Institut de veille sanitaire 2009.
- 28 Fisher JW, Mahle D, Abbas R. A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. *Toxicol Appl Pharmacol* 1998;**152** (2):339-59.
- 29 Sato A. Confounding factors in biological monitoring of exposure to organic solvents. *Int Arch Occup Environ Health* 1993;**65** (1 Suppl):S61-S67.

BMJ Open

30	Luce D, Stucker I, Icare Study Group. Investigation of occupational and environmental causes of respiratory cancers (ICARE): a multicenter, population-based case-control study in France. <i>BMC Public Health</i> 2011; 11 (1):928.
31	International Labour Office. International Standard Classification of Occupations. Geneva (Switzerland) 1968.
32	Institut National de la Statistique et des Etudes Economiques. Nomenclature des Activités Françaises, Révision 1. France 2000.
33	Fevotte J, Dananche B, Delabre L, <i>et al.</i> Matgene: a program to develop job-exposure matrices in the general population in France. <i>Ann Occup Hyg</i> 2011; 55 (8):865-78.
34	Wartenberg D, Reyner D, Scott CS. Trichloroethylene and cancer: epidemiologic evidence. Environ Health Perspect 2000; 108 Suppl 2 :161-76.
35	Raaschou-Nielsen O, Hansen J, McLaughlin JK, <i>et al.</i> Cancer risk among workers at Danish companies using trichloroethylene: a cohort study. <i>Am J Epidemiol</i> 2003; 158 (12):1182-92.
36	Boice JD, Jr., Marano DE, Cohen SS, <i>et al.</i> Mortality among Rocketdyne workers who tested rocket engines, 1948-1999. <i>J Occup Environ Med</i> 2006; 48 (10):1070-92.
37	 Hansen J, Sallmen M, Selden AI, et al. Risk of cancer among workers exposed to trichloroethylene: analysis of three Nordic cohort studies. J Natl Cancer Inst 2013;105 (12):869-77.
38	Radican L, Blair A, Stewart P, et al. Mortality of aircraft maintenance workers exposed to trichloroethylene and other hydrocarbons and chemicals: extended follow-up. J Occup Environ Med 2008; 50 (11):1306-19.
39	Mundt KA, Birk T, Burch MT. Critical review of the epidemiological literature on occupational exposure to perchloroethylene and cancer. <i>Int Arch Occup Environ Health</i> 2003; 76 (7):473-91.
40	Blair A, Petralia SA, Stewart PA. Extended mortality follow-up of a cohort of dry cleaners. Ann Epidemiol 2003; 13 (1):50-6.
41	Calvert GM, Ruder AM, Petersen MR. Mortality and end-stage renal disease incidence among dry cleaning workers. <i>Occup Environ Med</i> 2011; 68 (10):709-16.
42	Vaughan TL, Stewart PA, Davis S, <i>et al.</i> Work in dry cleaning and the incidence of cancer of the oral cavity, larynx, and oesophagus. <i>Occup Environ Med</i> 1997; 54 (9):692-5.
43	Fayossé A, Menvielle G, Cyr D, <i>et al.</i> Head and neck cancer and occupational exposure to chlorinated solvents: results from the ICARE study. <i>Occupational and Environmental Medicine</i> 2014; 71 (Suppl 1):A99-A100.
44	Rusyn I, Chiu WA, Lash LH, <i>et al.</i> Trichloroethylene: Mechanistic, epidemiologic and other supporting evidence of carcinogenic hazard. <i>Pharmacol Ther</i> 2014; 141 (1):55-68.
	25 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

- get B.B.

 Schonnahre S.

 Bernan D. Performance S.

 Control Work Environ Health 1995.

 Stengel B, Pisani P, Limasset JC, et al. Retrospective evaluation of occupational exposure to

Table I: Main	characteristics	of cases	and	controls
---------------	-----------------	----------	-----	----------

	Ca	ses	C	Controls
	n	%	n	%
Département				p=0.003
Calvados	23	7.8	104	13.4
Doubs+ Territoire de Belfort	1	0.3	31	4.0
Hérault	44	14.9	90	11.6
lsère	37	12.5	94	12.1
Loire Atlantique	38	12.8	93	12.0
Manche	37	12.5	65	8.4
Bas-Rhin	33	11.2	109	14.1
Haut-Rhin	9	3.0	29	3.7
Somme	54	18.2	112	14.5
Vendée	20	6.8	48	6.2
Age at interview, years				p<0.0001
Mean (95%CI)	58.0 (56.9-5	9.0)	60.4 (59.6	•
Class		/		· · · · · · · · · · · · · · · · · · ·
<50 years	51	17.2	160	20.6
50-59.9 years	109	36.8	157	20.3
60-69.9 years	99	33.4	246	31.8
\geq 70 years	37	12.6	210	27.3
Number of jobs held	57	12.0	212	p=0.01
Mean (95%Cl)	3.3 (2.9-3.6)		3.7 (3.4-3.8	•
	18		3.7 (3.4-3.8 13)
Range Socioeconomic status (the longest	10		15	
duration)				p=0.001
Farmers	3	1.1	29	р=0.001 3.8
Self-employed workers	14	5.1	25	3.3
	14	6.9	74	
Managers Intermediate white-collar workers				9.7
	28	10.1	131	17.3
Office and sales employees	150	54.1	375	49.4
Blue-collar workers	63	22.7	125	16.5
Missing	19		16	-
Smoking				p<0.0001
Never*	60	20.3	509	66.1
Former smokers#	46	15.5	134	17.4
Current smokers	190	64.2	127	16.5
Missing	-		5	
Pack-Years (Former and current)				p<0.0001
<6.89	23	9.9	100	38.5
6.9-19.9	34	14.6	87	33.5
20.0-35.24	78	33.5	47	18.1
≥35.25	98	42.1	26	10.0
Missing	3	-	6	-
Drinking (drink-years)				p<0.0001
Never	44	15.4	177	22.9
< 2.79	39	13.6	173	22.4
2.8-16.3	35	12.2	172	22.3
16.4-64.9	51	17.8	155	20.0
≥ 65.0	117	40.9	96	12.4
Missing	10		2	

*: Nonsmokers were subjects who had smoked fewer than 100 cigarettes or equivalent in their lifetime

#: Former smokers were subjects who had stopped smoking at least 2 years before diagnosis (cases)/interview (controls).

Table II: Association between head and neck cancer and exposure to selected solvents

Ca Co OR* 95% C Chlorinated solvents Chlorinated solvents 1 Ref. 10 Methylene chloride 264 728 1 Ref. 11 Trichloroethylene 240 697 1 Ref. 12 Perchloroethylene 268 744 1 Ref. 13 Petroleum solvents 251 705 1 Ref. 13 Petroleum solvents 251 705 1 Ref. 14 Special petroleum product 251 709 1 Ref. 16 Gasoil 264 731 1 Ref. 17 Benzene 250 709 1 Ref. 18 White-spirits 188 513 1 Ref. 19 Oxygenated solvents Diethyl ether 252 669 1 Ref. 23 Alcohols 152 394 1 Ref. 24 # OR adjusted for age at interview, depart * p<0.05 ** p<0.01 ** p<0.01 <th>ef. 14 30 1.09 0.46 to 2.5</th> <th>< median</th> Ca Co OR" 95% CI 7 7 15 1.34 0.42 to 4.28	ef. 14 30 1.09 0.46 to 2.5	< median	≥ median Ca Co OR [#] 95% CI OF	Continuous R [#] 95% Cl	< 10 years Ca Co OR [#] 95% Cl	≥ 10 years Ca Co OR [#] 95% Cl	Continuous
3 Chlorinated solvents 10 Methylene chloride 264 728 1 Ref. 11 Trichloroethylene 240 697 1 Ref. 12 Perchloroethylene 268 744 1 Ref. 13 Petroleum solvents 1 Ref. Ref. 14 Special petroleum product 251 705 1 Ref. 16 Gasoil 264 731 1 Ref. 17 Benzene 250 709 1 Ref. 18 White-spirits 188 513 1 Ref. 19 Oxygenated solvents 234 675 1 Ref. 20 Diethyl ether 252 669 1 Ref. 21 Ketones 234 675 1 Ref. 22 Alcohols 152 394 1 Ref. 24 # OR adjusted for age at interview, depart * p<0.05 ** p<0.01	ef. 14 30 1.09 0.46 to 2.5		Ca Co OR" 95% CI OF	R [#] 95% CI	Ca Co OR [#] 95% Cl	Co. Co. OD [#] 05% Cl	*
O Methylene chloride 264 728 1 Ref. 11 Trichloroethylene 240 697 1 Ref. 12 Perchloroethylene 268 744 1 Ref. 13 Petroleum solvents 251 705 1 Ref. 14 Special petroleum product 251 705 1 Ref. 16 Gasoil 264 731 1 Ref. 17 Benzene 250 709 1 Ref. 18 White-spirits 188 513 1 Ref. 19 Oxygenated solvents 224 669 1 Ref. 20 Diethyl ether 252 669 1 Ref. 21 Ketones 234 675 1 Ref. 22 Alcohols 152 394 1 Ref. 23 # OR adjusted for age at interview, depart * p<0.05 ** p<0.01		7 7 15 1.34 0.42 to 4.28				Ca CO OR 95% CI	OR [#] 95% CI
11 Trichloroethylene 240 697 1 Ref. 12 Perchloroethylene 268 744 1 Ref. 13 Petroleum solvents 251 705 1 Ref. 14 Special petroleum product 251 705 1 Ref. 15 Gasoil 264 731 1 Ref. 16 Gasoil 264 731 1 Ref. 17 Benzene 250 709 1 Ref. 18 White-spirits 188 513 1 Ref. 19 Oxygenated solvents 252 669 1 Ref. 20 Diethyl ether 252 394 1 Ref. 21 Ketones 234 675 1 Ref. 22 Alcohols 152 394 1 Ref. 24 # OR adjusted for age at interview, depart * p<0.05		7 7 15 1.34 0.42 to 4.28			I	1	
12 Perchloroethylene 268 744 1 Ref. 13 Petroleum solvents 14 Special petroleum product 251 705 1 Ref. 15 Gasoil 264 731 1 Ref. 16 Gasoil 264 731 1 Ref. 17 Benzene 250 709 1 Ref. 18 White-spirits 188 513 1 Ref. 19 Oxygenated solvents 0 1 Ref. 20 Diethyl ether 252 669 1 Ref. 21 Ketones 234 675 1 Ref. 22 Alcohols 152 394 1 Ref. 23 # OR adjusted for age at interview, depart * p<0.05	ef. 38 60 2.15** 1.21 to 3.8		7 15 0.87 0.25 to 2.99 1.0	01 0.97 to 1.06	7 21 0.85 0.28 to 2.56	7 9 1.65 0.42 to 6.53	0.99 0.93 to 1.05
3 Petroleum solvents 4 Petroleum solvents 5 Special petroleum product 251 705 1 Ref. 16 Gasoil 264 731 1 Ref. 17 Benzene 250 709 1 Ref. 18 White-spirits 188 513 1 Ref. 19 Oxygenated solvents 0 252 669 1 Ref. 20 Diethyl ether 252 669 1 Ref. 21 Ketones 234 675 1 Ref. 22 Alcohols 152 394 1 Ref. 23 # OR adjusted for age at interview, depart * p<0.05		1 20 30 2.16* 1.02 to 4.58	18 30 2.13 0.94 to 4.84 1.0	02* 1.01 to 1.04	25 47 1.67 0.86 to 3.24	13 13 4.44** 1.56 to 12.6	1.06** 1.01 to 1.12
14 Special petroleum solvents 15 Special petroleum product 251 705 1 Ref. 16 Gasoil 264 731 1 Ref. 17 Benzene 250 709 1 Ref. 18 White-spirits 188 513 1 Ref. 19 Oxygenated solvents 252 669 1 Ref. 20 Diethyl ether 252 669 1 Ref. 21 Ketones 234 675 1 Ref. 22 Alcohols 152 394 1 Ref. 23 # OR adjusted for age at interview, depart * p<0.05	ef. 10 13 2.97* 1.05 to 8.4	5 8 7 4.09* 1.15 to 14.6	2 6 1.44 0.18 to 11.6 1.0	00 0.99 to 1.02	8 9 2.66 0.75 to 9.40	2 4 3.75 0.64 to 21.9	1.06 0.97 to 1.17
Special petroleum product 251 705 1 Ref. Gasoil 264 731 1 Ref. I7 Benzene 250 709 1 Ref. White-spirits 188 513 1 Ref. Oxygenated solvents 0 252 669 1 Ref. Diethyl ether 252 669 1 Ref. 22 Alcohols 152 394 1 Ref. 23 4 675 1 Ref. 24 # OR adjusted for age at interview, depart * 25 * p<0.05			I I				
Gasoil 264 731 1 Ref. Benzene 250 709 1 Ref. White-spirits 188 513 1 Ref. Oxygenated solvents 0 252 669 1 Ref. Diethyl ether 252 669 1 Ref. 22 Alcohols 152 394 1 Ref. 23 4 Condis 152 394 1 Ref. 24 # OR adjusted for age at interview, depart * p<0.05	ef. 27 54 1.40 0.74 to 2.6	5 21 27 1.51 0.68 to 3.35	6 27 1.25 0.45 to 3.45 1.0	00 0.99 to 1.01	19 30 1.47 0.67 to 3.20	8 24 1.30 0.47 to 3.65	0.99 0.94 to 1.04
17 Benzene 250 709 1 Ref. 18 White-spirits 188 513 1 Ref. 19 Oxygenated solvents 0 0 1 Ref. 20 Diethyl ether 252 669 1 Ref. 21 Ketones 234 675 1 Ref. 23 Alcohols 152 394 1 Ref. 24 # OR adjusted for age at interview, depart * p<0.05	ef. 14 26 1.79 0.75 to 4.2	9 6 12 1.14 0.31 to 4.29	8 14 2.52 0.82 to 7.74 1.0	00 0.97 to 1.03	12 16 2.89* 1.03 to 8.08	2 10 0.56 0.09 to 3.31	1.02 0.95 to 1.10
White-spirits 188 513 1 Ref. 19 Oxygenated solvents Ref. 20 Diethyl ether 252 669 1 Ref. 21 Ketones 234 675 1 Ref. 23 Alcohols 152 394 1 Ref. 24 # OR adjusted for age at interview, depart * p<0.05	ef. 28 50 1.65 0.87 to 3.1	3 19 25 1.59 0.69 to 3.64	9 25 1.74 0.67 to 4.53 1.0	02 0.89 to 1.17	21 35 1.77 0.85 to 3.67	7 15 1.34 0.38 to 4.68	1.00 0.94 to 1.06
20 Diethyl ether 252 669 1 Ref. 21 Ketones 234 675 1 Ref. 22 Alcohols 152 394 1 Ref. 23 4 POR adjusted for age at interview, depart * p<0.05	ef. 87 247 1.08 0.73 to 1.6	0 42 118 1.04 0.62 to 1.74	45 129 1.08 0.65 to 1.78 1.0	00 0.98 to 1.02	50 153 0.87 0.54 to 1.40	37 94 1.45 0.83 to 2.52	1.01 0.99 to 1.04
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	I				I	1	
$\begin{array}{cccccc} & & & & & & & & & & & & & & & & $	ef. 25 88 0.65 0.36 to 1.1	9 13 44 0.89 0.41 to 1.95	12 44 0.46 0.19 to 1.10 0.7	70 0.41 to 1.27	9 25 1.07 0.39 to 2.91	16 63 0.52 0.25 to 1.07	0.98 0.95 to 1.01
23 Alcohols 152 394 1 Ref. 24 # OR adjusted for age at interview, depart * $p < 0.05$ 26 * $p < 0.01$	ef. 44 83 1.61 0.96 to 2.7	0 28 42 2.27* 1.16 to 4.44	16 41 1.10 0.52 to 2.31 1.0	01 0.99 to 1.02	32 55 1.71 0.94 to 3.11	12 28 1.42 0.58 to 3.48	1.02 0.98 to 1.06
 4 # OR adjusted for age at interview, depart * p<0.05 * p<0.01 	ef. 123 364 0.83 0.57 to 1.2	0 57 180 0.68 0.43 to 1.10	66 184 0.95 0.61 to 1.48 1.0	01 0.98 to 1.03	67 168 0.93 0.59 to 1.45	56 196 0.71 0.44 to 1.13	0.99 0.97 to 1.01
8 9 0 1 2 3 4 5 6					67 168 0.93 0.59 to 1.45		
37 38							
9 9							
40							
1							
2							
13							
14 15							
6	For pe	er review only - h	ttp://bmjopen.bmj.c	com/site/a	bout/guidelines.	khtml	
145 Protected by copyright. 84 142 Protected by copyright.							

to 4,04 0.15 to 15,8 0.02 to 2,18 0.35 to 4,77 0.34 to 24,1 0.53	
- to 15,8 0.02 to 2,18 0.35 to 4,77 0.34	
to 2,18 0.35 to 4,77 0.34	
to 2,18 0.35 to 4,77 0.34	
to 4,77 0.34	
to 24,1 0.53	


Ever exposure to	Controls	Cases	OR [#]	CI 95%	р	Cases	OR [#]	opharynx CI 95%	р	Cases	OR [#] ່	opharynx Cl 95%	р	Cases	OR [#]	Larynx CI 95%	р	
Methylene chloride Trichloroethylene Perchloroethylene Special petroleum product Gasoil Benzene White-spirits Diethyl ether Ketones Alcohols	30 60 13 54 26 50 247 88 83 365	5 12 1 10 2 9 32 10 13 41	1.34 2.12 0.98 1.79 0.88 1.79 1.54 0.91 1.58 1.02	0.44 to 4.13 0.97 to 4.60 0.11 to 8.47 0.78 to 4.09 0.18 to 4.32 0.76 to 4.22 0.90 to 2.66 0.41 to 2.06 0.77 to 3.25 0.61 to 1.73	0.60 0.98 0.17 0.87 0.18 0.12 0.83 0.22 0.93	2 13 5 7 5 9 21 8 14 40	0.42 1.66 3.43 * 0.87 1.90 1.39 0.54 * 0.51 1.24 0.59 *	0.09 to 2.02 0.78 to 3.54 1.01 to 11.8 0.35 to 2.17 0.60 to 6.03 0.58 to 3.31 0.30 to 0.95 0.22 to 1.20 0.62 to 2.48 0.36 to 0.97	0.28 0.18 0.76 0.27 0.45 0.03 0.12 0.54 0.03	2 3 2 2 10 3 5 15	1.23 2.45 - 1.05 3.60 0.97 1.67 0.74 1.93 1.43	0.21 to 7.18 0.57 to 10.5 - 0.19 to 5.78 0.55 to 23.4 0.65 to 4.29 0.18 to 3.05 0.59 to 6.26 0.57 to 3.56	0.81 0.22 - 0.95 0.18 0.97 0.28 0.67 0.27 0.44	4 10 4 7 4 6 20 2 11 22	2.0 3.80** 7.95** 2.24 2.51 2.07 1.70 0.30 2.66* 0.89	0.56 to 7.20 1.55 to 9.32 1.92 to 32.9 0.82 to 6.09 0.66 to 9.53 0.72 to 5.97 0.86 to 3.37 0.07 to 1.40 1.17 to 6.07 0.46 to 1.75	0.28 0.003 0.004 0.11 0.17 0.17 0.12 0.12 0.12 0.02 0.74	
<pre># OR adjusted for age at in * p<0.05</pre>	iterview, d	lepartm	ent, alco	ohol and toba	acco co	onsumpti	on.											
** p<0.01																		

Page 31 of 39

BMJ Open


SUPPLEMENTARY MATERIALS

Supplementary - Figures 1










Page 33 of 39

 BMJ Open

Supplementary - Figures 2



For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Table S-I: Association between head and neck cancer site and exposure to chlorinated solvents

	Controlo	0		al cavity	-	6		opharynx	-	6		opharynx		Larynx Cases OR [#] CI 95%			
	Controls	Cases	OR [#]	CI 95%	р	Cases	OR [#]	CI 95%	р	Cases	OR [#]	CI 95%	р	Cases	OR [#]	CI 95%	р
Methylene chloride																	
Ever exposed	30	5	1.34	0.44 to 4.13	0.60	2	0.42	0.09 to 2.02	0.28	2	1.23	0.21 to 7.18	0.81	4	2.0	0.56 to 7.20	0.28
Cumulative Exposure Index																	
< median	15	2	1.39	0.27 to 7.16	0.69	2	0.92	0.17 to 4.94	0.92	-	-	-	-	3	3.12	0.65 to 14.9	0.15
≥ median	15	3	1.30	0.29 to 5.90	0.73	-	-	-	-	2	1.78	0.24 to 13.5	0.57	1	0.95	0.10 to 9.29	0.96
Duration of exposure																	
< 10 years	21	2	0.79	0.16 to 4.05	0.78	1	0.32	0.04 to 2.75	0.30	1	1.11	0.10 to 12.0	0.93	3	2.35	0.54 to 10.3	0.25
≥ 10 years	9	3	2.52	0.52 to 12.3	0.25	1	0.64	0.06 to 6.36	0.70	1	1.53	0.12 to 19.6	0.74	1	1.52	0.14 to 16.7	0.73
Trichloroethylene																	
Ever exposed	60	12	2.12	0.97 to 4.60	0.058	13	1.66	0.78 to 3.54	0.18	3	2.45	0.57 to 10.5	0.22	10	3.80**	1.55 to 9.32	0.003
Cumulative Exposure Index																	
< median	30	4	1.38	0.42 to 4.57	0.59	9	2.30	0.93 to 5.71	0.07	1	1.22	0.12 to 12.1	0.86	6	4.22*	1.34 to 13.3	0.013
≥ median	30	8	2.73*	1.02 to 7.30	0.04	4	0.97	0.27 to 3.42	0.96	2	4.13	0.72 to 23.7	0.11	4	3.25	0.92 to 11.4	0.067
Duration of exposure																	
< 10 years	47	6	1.16	0.42 to 3.22	0.78	9	1.48	0.62 to 3.49	0.37	3	2.31	0.52 to 10.3	0.27	8	3.47*	1.28 to 9.41	0.014
≥ 10 years	13	6	6.84**	2.11 to 22.1	0.001	4	2.54	0.63 to 10.3	0.19	õ	-	-	-	2	4.73	0.86 to 26.0	0.074
Perchloroethylene																	
Ever exposed	13	1	0.98	0.11 to 8.47	0.98	5	3.43*	1.01 to 11.8	0.05	0				4	7.95**	1.92 to 32.9	0.004
Cumulative Exposure Index	15		0.90	0.1110 0.47	0.90		5.75	1.01 10 11.0	0.00	0	-	-	-	-	1.55	1.52 10 52.5	0.004
< median	7	1	1.59	0.17 to 14.7	0.68	3	3.76	0.75 to 18.9	0.11	0				4	15.8***	3.19 to 77.8	0.0007
< median ≥ median	6	0	1.55	0.17 10 14.7	0.08	2	2.59	0.32 to 20.7	0.36	0	-	-	-	0	15.0	3.191077.0	0.0007
Duration of exposure	0	0	-	-	0.99	2	2.59	0.32 10 20.7	0.30	0	-	-	-	0	-	-	-
< 10 years	9	0			0.99	4	3.55	0.80 to 15.7	0.09	0				4	9.96**	2.04 to 48.5	0.004
< 10 years ≥ 10 years	9	1	- 9.50	- 0.89 to 101	0.99	4	3.55	0.001.01 5	0.04		-	-	-	•			
# OR adjusted for age at	interview	denartm	ont alco			umption											
, .	interview,	ucpurun	icit, aice			umption	•										
* p<0.05																	
** p<0.01																	
μ<0.01																	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

Table S-II: Association between head and neck cancer site and exposure to petroleum solvents

	.			al cavity		-		pharynx		-		opharynx		-	Larynx		
	Controls	Cases	OR [#]	CI 95%	р	Cases	OR [#]	CI 95%	р	Cases	OR [#]	CI 95%	р	Cases	OR [#]	CI 95%	р
Special petroleum product																	
Ever exposed	54	10	1.79	0.78 to 4.09	0.17	7	0.87	0.35 to 2.17	0.76	2	1.05	0.19 to 5.78	0.95	7	2.24	0.82 to 6.09	0.11
Cumulative Exposure Index																	
< median	27	7	1.86	0.66 to 5.25	0.24	5	0.86	0.28 to 2.63	0.79	2	1.43	0.24 to 8.63	0.69	7	3.12*	1.04 to 9.33	0.04
≥ median	27	3	1.81	0.50 to 6.59	0.37	2	0.96	0.20 to 4.57	0.95	0	-	-	-	0	-	-	-
Duration of exposure																	
< 10 years	30	5	1.30	0.43 to 3.97	0.64	6	1.12	0.39 to 3.18	0.83	1	0.79	0.08 to 7.41	0.83	7	3.31*	1.12 to 9.74	0.03
≥ 10 years	24	5	2.75	0.85 to 8.85	0.091	1	0.39	0.05 to 3.19	0.38	1	1.55	0.13 to 19.0	0.73	0	-	-	-
Gasoil																	
Ever exposed	26	2	0.88	0.18 to 4.32	0.87	5	1.90	0.60 to 6.03	0.27	2	3.60	0.55 to 23.4	0.18	4	2.51	0.66 to 9.53	0.17
Cumulative Exposure Index	20	2	0.00	0.10104.52	0.07	5	1.30	0.00 10 0.00	0.21	2	5.00	0.55 10 25.4	0.10	-	2.51	0.00 10 3.55	0.17
< median	12	0			0.99	3	1.81	0.38 to 8.53	0.45	1	3.24	0.24 to 44.3	0.37	2	1.62	0.25 to 10.6	0.61
< median ≥ median	14	2	- 1.91	- 0.37 to 9.78	0.99	2	1.80	0.33 to 9.88	0.49	1	3.57	0.27 to 47.1	0.33	2	3.60	0.62 to 20.7	0.01
Duration of exposure	14	2	1.91	0.37 10 9.76	0.44	2	1.00	0.33 10 9.66	0.49	1	3.57	0.27 10 47.1	0.55	2	3.00	0.62 10 20.7	0.15
< 10 vears	16	2	1.62	0.30 to 8.65	0.57	4	3.02	0.80 to 11.5	0.10	1	3.38	0.28 to 41.1	0.33	4	4.42*	1.04 to 18.8	0.04
	10	2 0	1.02	-	0.57	4	0.62		0.10		3.38 4.87		0.33	4	4.42		0.04
≥ 10 years	10	0	-	-	0.99		0.62	0.06 to 6.36	0.68	1	4.87	0.33 to 71.7	0.24	0	-	-	-
Benzene																	
Ever exposed	50	9	1.79	0.76 to 4.22	0.18	9	1.39	0.58 to 3.31	0.45	2	0.97	0.17 to 5.43	0.97	6	2.07	0.72 to 5.97	0.17
Cumulative Exposure Index																	
< median	25	6	1.86	0.63 to 5.52	0.26	6	1.17	0.40 to 3.43	0.77	1	0.78	0.08 to 7.72	0.82	5	2.57	0.75 to 8.79	0.13
≥ median	25	3	1.62	0.42 to 6.22	0.48	3	2.06	0.53 to 8.01	0.29	1	1.21	0.10 to 14.8	0.88	1	0.90	0.09 to 8.79	0.92
Duration of exposure																	
< 10 years	35	5	1.47	0.51 to 4.29	0.48	8	1.72	0.67 to 4.42	0.25	1	0.87	0.09 to 8.12	0.90	6	3.03*	1.02 to 9.18	0.05
≥ 10 years	15	4	2.32	0.57 to 9.48	0.24	1	0.56	0.06 to 5.07	0.60	1	0.93	0.06 to 13.6	0.95	0	-	-	-
White-spirits																	
Ever exposed	247	32	1.54	0.90 to 2.66	0.12	21	0.54*	0.30 to 0.95	0.03	10	1.67	0.65 to 4.29	0.28	20	1.70	0.86 to 3.37	0.12
Cumulative Exposure Index																	
< median	117	12	1.20	0.56 to 2.54	0.64	10	0.53	0.25 to 1.15	0.10	8	2.75	0.91 to 8.32	0.074	10	1.76	0.75 to 4.17	0.19
≥ median	129	20	1.75	0.91 to 3.37	0.09	11	0.51	0.23 to 1.09	0.08	2	0.52	0.10 to 2.71	0.43	10	1.70	0.71 to 4.06	0.23
Duration of exposure	120	20	1.70	0.01 10 0.01	0.00		0.01	0.2010 1.00	0.00	-	0.02	0.10 10 2.7 1	0.40	10	1.70	0.7 1 10 4.00	0.20
< 10 years	152	14	0.97	0.48 to 1.96	0.93	11	0.41*	0.20 to 0.85	0.02	9	2.02	0.70 to 5.84	0.19	14	1.68	0.77 to 3.64	0.19
≥ 10 years	94	18	2.51**	1.25 to 5.02	0.009	10	0.75	0.33 to 1.69	0.48	1 1	0.47	0.05 to 4.23	0.50	6	1.73	0.62 to 4.83	0.29
,						-		0.55 10 1.09	0.40	1	0.47	0.03 10 4.23	0.50	0	1.75	0.02 10 4.05	0.23
# OR adjusted for age at	interview,	departm	ient, alco	phol and toba	cco cons	sumption											
* p<0.05																	
•																	
** p<0.01																	
•																	

* p<0.05

 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

Table S-III: Association between head and neck cancer site and exposure to oxygenated solvents

				al cavity				opharynx				opharynx				arynx	
	Controls	Cases	OR [#]	CI 95%	р	Cases	OR [#]	CI 95%	р	Cases	OR [#]	CI 95%	р	Cases	OR [#]	CI 95%	р
Diethyl ether																	
Ever exposed	88	10	0.91	0.41 to 2.06	0.83	8	0.51	0.22 to 1.20	0.12	3	0.74	0.18 to 3.05	0.67	2	0.30	0.07 to 1.40	0.12
Cumulative Exposure Index																	
< median	44	6	1.57	0.56 to 4.42	0.39	3	0.47	0.13 to 1.69	0.24	1	0.64	0.07 to 5.82	0.69	1	0.43	0.05 to 3.46	0.42
≥ median	44	4	0.51	0.15 to 1.74	0.28	5	0.51	0.17 to 1.56	0.24	2	0.73	0.12 to 4.58	0.74	1	0.21	0.03 to 1.86	0.16
Duration of exposure																	
< 10 years	25	4	1.49	0.42 to 5.35	0.54	2	0.64	0.13 to 3.09	0.57	1	0.98	0.10 to 9.76	0.98	1	0.77	0.09 to 6.62	0.81
≥ 10 years	63	6	0.71	0.26 to 1.95	0.50	6	0.46	0.18 to 1.24	0.12	2	0.65	0.12 to 3.64	0.62	1	0.18	0.02 to 1.48	0.11
Ketones	00	•	0.7 1	0.20 10 1.00	0.00	Ŭ	0.10	0.10101.21	0.12	-	0.00	0.12 10 0.01	0.02		0.10	0.02 10 1110	0
Ever exposed	83	13	1.58	0.77 to 3.25	0.22	14	1.24	0.62 to 2.48	0.54	5	1.93	0.59 to 6.26	0.27	11	2.66*	1.17 to 6.07	0.020
Cumulative Exposure Index	05	15	1.50	0.77 10 3.25	0.22	14	1.24	0.02 10 2.40	0.04	5	1.95	0.59 10 0.20	0.27	••	2.00	1.17 10 0.07	0.020
< median	42	8	2.08	0.83 to 5.23	0.13	10	1.94	0.82 to 4.58	0.12	4	4.37*	1.13 to 16.9	0.032	7	3.46*	1.24 to 9.65	0.018
< median ≥ median	42	5	1.17	0.40 to 3.42	0.13	4	0.65	0.21 to 2.07	0.12	1	0.51	0.05 to 4.87	0.55	4	2.04	0.60 to 6.98	0.25
Duration of exposure	41	5	1.17	0.40 10 3.42	0.77	4	0.05	0.21 10 2.07	0.47	1	0.51	0.05 10 4.67	0.55	4	2.04	0.00 10 0.96	0.25
		0	4.05	0.50 += 0.00	0.50	11	4 40	0.05 10.0 45	0.00	2	4 70	0 40 40 0 05	0.45	10	3.34**	1.38 to 8.10	0.008
< 10 years	55 28	8 5	1.35 2.19	0.56 to 3.26	0.50		1.43	0.65 to 3.15	0.38 0.81	3 2	1.70	0.42 to 6.95	0.45	10			
≥ 10 years	28	5	2.19	0.70 to 6.81	0.18	3	0.85	0.23 to 3.20	0.81	2	2.46	0.37 to 16.4	0.35	1	0.93	0.11 to 7.99	0.95
Alcohols																	
Ever exposed	365	41	1.02	0.61 to 1.73	0.93	40	0.59*	0.36 to 0.97	0.03	15	1.43	0.57 to 3.56	0.44	22	0.89	0.46 to 1.75	0.74
Cumulative Exposure Index																	
< median	180	17	0.80	0.41 to 1.58	0.52	18	0.48*	0.25 to 0.91	0.02	11	1.86	0.67 to 5.16	0.23	11	0.77	0.34 to 1.77	0.54
≥ median	184	24	1.22	0.66 to 2.27	0.53	22	0.68	0.37 to 1.25	0.21	4	0.73	0.20 to 2.70	0.63	11	1.03	0.45 to 2.37	0.93
Duration of exposure																	
< 10 years	168	20	1.05	0.55 to 2.01	0.87	20	0.62	0.34 to 1.15	0.12	10	1.91	0.68 to 5.38	0.22	15	1.24	0.58 to 2.64	0.58
≥ 10 years	196	21	0.96	0.51 to 1.83	0.90	20	0.54	0.29 to 1.01	0.055	5	0.82	0.23 to 2.87	0.75	7	0.57	0.22 to 1.46	0.24
** p<0.01																0.22 to 1.46	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

	Item No		Page ir main
		Recommendation	doc
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly used term in the title or the abstract	3
		(<i>b</i>) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of	7
C		recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment	7-8
*		and control selection. Give the rationale for the choice of cases and controls	
		(b) For matched studies, give matching criteria and the number of controls per	-
		case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and	8-9
		effect modifiers. Give diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of methods of	9
measurement		assessment (measurement). Describe comparability of assessment methods if	
		there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	10
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,	10
		describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for	10-11
		confounding	
		(b) Describe any methods used to examine subgroups and interactions	10-11
		(c) Explain how missing data were addressed	
		(d) If applicable, explain how matching of cases and controls was addressed	
		(<u>e</u>) Describe any sensitivity analyses	11
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially	Χ
		eligible, examined for eligibility, confirmed eligible, included in the study,	
		completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	X
		(c) Consider use of a flow diagram	X
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social)	12 +
		and information on exposures and potential confounders	Table
		(b) Indicate number of participants with missing data for each variable of interest	12 +
			Table
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure	Table
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates	12-14

For peer review only - http://bmjopen!bmj.com/site/about/guidelines.xhtml

	(b) Report category boundaries when continuous variables were categorized Table (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	(b) Report category boundaries when continuous variables were categorized Table (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period		and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Tables
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period			Table
a meaningful time period	a meaningful time period	a meaningful time period			
			Ś	(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	



Other analyses	17	Report other analyses done-eg analyses of subgroups and interactions, and sensitivity	14 ·
		analyses	Tabl
			and
			Supp
			Ma
Discussion			
Key results	18	Summarise key results with reference to study objectives	16
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.	20-2
		Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations,	16-1
		multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	22
Other informati	on		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable,	23
		for the original study on which the present article is based	

*Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

BMJ Open

Occupational exposure to solvents and risk of head and neck cancer in women: a population-based case-control study in France

Journal:	BMJ Open
Manuscript ID	bmjopen-2016-012833.R1
Article Type:	Research
Date Submitted by the Author:	26-Sep-2016
Complete List of Authors:	Carton, Matthieu; INSERM, Epidemiologic Cohorts Unit ; University of Versailles St-Quentin, UMRS1018 , UMS 011 Barul, Christine; Inserm U 1085, Institut de Recherche Santé Environnement & Travail (IRSET) Menvielle, Gwenn; INSERM, Department of social epidemiology; Sorbonne University, Department of social epidemiology Cyr, Diane; INSERM, Epidemiologic Cohorts Unit – UMS 011 INSERM – UVSQ; University of Versailles St-Quentin, Sanchez, Marie; INSERM, CESP Centre for Research in Epidemiology and Population Health, Environmental epidemiology of cancer; University of Paris Sud 11, Pilorget, Corinne; Institut de Veille Sanitaire, Département Santé Travail; University Lyon 1, University Lyon, Unité mixte de recherche épidémiologique et de surveillance en transport, travail et environnement (Umrestte), F-69622, Umrestte Trétarre, Brigitte; Hérault Cancer Registry, Stücker, Isabelle; INSERM, CESP Centre for Research in Epidemiology and Population Health, Environmental epidemiology of cancer; University of Paris Sud 11, University Lyon 1, Universite Presearch in Epidemiology and Population Health, Environmental epidemiology of cancer; University of Paris Sud 11, Luce, Danièle; INSERM, U 1085_IRSET ; University of Rennes 1,
Primary Subject Heading :	Occupational and environmental medicine
Secondary Subject Heading:	Oncology, Public health, Ear, nose and throat/otolaryngology, Epidemiolog
Keywords:	head and neck, Cancer, trichloroethylene, perchloroethylene, occupationa exposures, women

SCHOLARONE[™] Manuscripts

2

3 4

5

6

7

8 9 10

11

12

13 14

15

16

17

18 19

20

21

22

23 24

25

26

27

28

29 30 31

32 33

34

35

36

37 38

39

40

41

42 43

44

45

46

47 48

49

50

51

52 53

54

55 56

57 58

59

60

Title Occupational exposure to solvents and risk of head and neck cancer in women: a population-based case-control study in France **Running title** Head and neck cancer and occupational exposure to solvents in women Complete names, academic degrees and affiliations (to the department level) of all authors Matthieu Carton^{1,2}, Christine Barul⁸, Gwenn Menvielle⁹, Diane Cyr^{1,2}, Marie Sanchez^{3,4}, Corinne Pilorget^{5,6}, Brigitte Trétarre⁷, Isabelle Stücker^{3,4}, Danièle Luce⁸ for the Icare Study Group[#]. ¹ Inserm, Population-based Epidemiologic Cohorts Unit, UMS 011, Villejuif, France ² University of Versailles St-Quentin, UMRS 1018, Villejuif, France ³ Inserm, CESP Centre for research in Epidemiology and Population Health, UMRS 1018, Environmental epidemiology of cancer Team, Villejuif, France ⁴ University Paris-Sud, UMRS 1018, Villejuif, France ⁵ French institute for public health surveillance, Department of occupational health, Saint Maurice, France ⁶ UMRESTTE (Epidemiological Research and Surveillance Unit in Transport, Occupation and Environment), University Claude Bernard, Lyon, France ⁷ Hérault Cancer Registry, Montpellier, France ⁸ Inserm U 1085 – Institut de Recherche Santé Environnement & Travail (IRSET), Faculté de Médecine, Pointeà-Pitre. France ⁹ Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), F75012, Paris, France #: Members of Icare Study Group Registre des cancers du Calvados, France (Anne-Valérie Guizard) ; Registre des cancers du Doubs, France (Arlette Danzon, Anne-Sophie Woronoff) ; Registre des cancers du Bas-Rhin, France (Velten Michel) ; Registre des cancers du Haut-Rhin, France (Antoine Buemi, Émilie Marrer); Registre des cancers de l'Hérault, France (Brigitte Tretarre) ; Registre des cancers de l'Isère. France (Marc Colonna, Patricia Delafosse) ; Registre des cancers de Loire-Atlantique-Vendée, France (Paolo Bercelli, Florence Molinie) ; Registre des cancers de la Manche, France (Simona Bara) ; Registre des cancers de la Somme, France (Benedicte Lapotre-Ledoux, Nicole Raverdy); Inserm, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France (Sylvie Cénée, Oumar Gaye, Florence Guida, Farida Lamkarkach, Loredana Radoï, Marie Sanchez, Isabelle Stücker); Inserm Epidemiologic Cohorts Unit - UMS 011 INSERM-UVSQ, Villejuif, France (Matthieu Carton, Diane Cyr, Annie Schmaus) University Lyon 1, UMRESTTE, Lyon, France: Joëlle Févotte French Institute for Public Health Surveillance, Department of Occupational Health, Saint Maurice, France: **Corinne Pilorget** Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France (Gwenn Menvielle) Inserm U 1085 - IRSET, Pointe-à-Pitre, France (Danièle Luce) Institution at which the work was performed

Inserm, CESP Centre for research in Epidemiology and Population Health, UMRS 1018

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Indication of and complete contact information (including email address) for the corresponding author Danièle Luce: daniele.luce@inserm.fr Inserm U 1085 - Irset Faculté de Médecine Campus de Fouillole BP 145 97154 Pointe-à-Pitre Téléphone : +33 (0)2 23 23 69 11 +33 (0)2 23 23 50 55 Télécopie :

A Conflict of Interest Statement (a short statement either disclosing conflicts or declaring that no conflicts exist) The authors declare no conflict of interest

Contributors

MC and DL designed the current study, conducted the analyses and drafted the manuscript; CB, GM contributed to the statistical analysis and interpretation of the results. DC, CP, BT were involved in data collection, management and quality control. DL and IS are the principal investigators of the ICARE study, conceived this study and coordinated the original collection of the data. All the authors critically reviewed and revised the manuscript; and gave their approval for its final version.

Manuscript word count 4 653

BMJ Open

Abstract

Objective: Our objective was to investigate the association between head and neck cancer and occupational exposure to chlorinated, oxygenated and petroleum solvents in women. Methods: ICARE, a French population-based case-control study, included 296 squamous cell carcinomas of the head and neck (HNSCC) in women and 775 female controls. Lifelong occupational history was collected. Job-exposure matrices allowed to assess exposure to five chlorinated solvents (carbon tetrachloride; chloroform; methylene chloride; perchloroethylene; trichloroethylene), 5 petroleum solvents (benzene; special petroleum product; gasoline; white-spirits and other light aromatic mixtures; diesel, fuels and kerosene) and 5 oxygenated solvents (alcohols; ketones and esters; ethylene glycol; diethyl ether; tetrahydrofuran). Odds ratio (ORs) and 95% confidence intervals (CI), adjusted for smoking, alcohol drinking, age and department, were estimated with logistic models. Results: Elevated ORs were observed among women ever exposed to perchloroethylene (OR=2.97, 95%CI: 1.05-8.45) and trichloroethylene (OR=2.15, 95%CI: 1.21-3.81). These ORs increased with exposure duration- (respectively OR=3.75, 95%CI: 0.64-21.9 and OR=4.44, 95%CI: 1.56-12.6 for ten years or more). No significantly increased risk of HNSCC was found for occupational exposure to the other chlorinated, petroleum or oxygenated solvents. *Conclusions*: These findings suggest that exposure to perchloroethylene or trichloroethylene may increase the risk of HNSCC in women. In our study, there is no clear evidence that the BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

other studied solvents are risk factors for HNSCC.

Keywords: head and neck; cancer; trichloroethylene; perchloroethylene; occupational exposures; women; solvents

Strengths and limitations

Little is known about occupational risk factors for head and neck cancer in women. Our study is one of the largest studies on this topic.

The study was population based; exposure to solvents was assessed from the entire occupational history, obtained from in-person interviews.

Special attention was paid to adjustment for alcohol and tobacco consumption

Exposure assessment through job-exposure matrices may entail misclassification of exposure, which is likely to be nondifferential.

Despite a relatively large number of cases, statistical power was limited for in-depth analyses by cancer sites.

Data sharing statement: No additional data are available.

Introduction

Compared to other European Union countries, head and neck cancers are frequent in France [1]. Age-standardized (world population) incidence rates in 2012 in France were 16.1 per 100,000 for lip, oral cavity and pharynx (LOCP) cancers and 5.4 per 100,000 for laryngeal cancer in men, and 5.6 per 100,000 for LOCP and 0.9 per 100,000 for laryngeal cancer in women. Moreover, in 1980–2012, the incidence of LOCP cancer and laryngeal cancer increased by 60% and 50% respectively in women, while it decreased by 60% and 62% respectively in men [2].

Tobacco smoking and alcohol consumption are well established major risk factors for these cancers [3], and the joint effect of tobacco and alcohol is at least multiplicative [4].

In addition to these major risk factors, several studies have investigated the role of occupational exposures in the occurrence of head and neck cancers. Thus, some occupations in men [5-17] and women [14, 18-21] were associated with the risk of developing head and neck cancer.

In a previous analysis by occupation among women [22], we found a high risk of head and neck cancer associated with various occupations and industries, among them electrical and electronic equipment assemblers, radio, television and communication equipment manufacturing, flame cutters, welders and printers, which suggested a possible role of exposure to solvents. Some studies have shown an increased risk of head and neck cancer associated with exposure to solvents [23, 24]. Some solvents such as trichloroethylene [25], perchloroethylene [25] or benzene [26] are classified as proven or probable carcinogens by IARC, but for cancer sites other than head and neck.

The majority of results on the association between solvent exposures and cancers of the upper aerodigestive tract were observed in studies conducted in men and very few studies

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

were conducted among women. However, chlorinated and oxygenated solvents are commonly used by women [27]. In addition, circumstances of exposure can vary between men and women and some studies have suggested gender differences in the toxicokinetics of solvents [28, 29]. ICARE (Investigation of occupational and environmental CAuses of .ge. .t exposures to chlor. REspiratory cancers), one of the largest population-based case-control studies of head and neck cancer, offers the opportunity to study the association between cancer of the head and neck and occupational exposures to chlorinated, oxygenated and petroleum solvents in women.

Study population

ICARE has been described in detail previously [30]. Briefly, ICARE is a multi-center, population-based case-control study, which included a group of 2926 lung cancer cases, a group of 2415 head and neck cancer cases, and a common control group of 3555 subjects. Incident cases were identified in collaboration with cancer registries in 10 geographical areas in France. All incident primary cancer cases of the head and neck diagnosed between 2001 and 2007 were included, comprising malignant neoplasms of the lip, oral cavity and pharynx (C00-C14), nasal cavity and accessory sinuses (C30.0, C31) and larynx (C32) as coded by the International Classification of Diseases for Oncology, third edition (ICD-O-3). Included cases were histologically confirmed cases, aged 18 years to 75 years at diagnosis. All histological types were included. The control group was a random sample of the population of the same geographical areas, with a distribution by sex and age comparable to that of both head and neck cancer and lung cancer cases, and a distribution by socioeconomic status comparable to that of the general population. Subjects were interviewed face to face, using a standardized questionnaire collecting information on lifetime tobacco and alcohol consumption, residential history, and a detailed description of occupational history. Participation rates were 80.6% among controls and 82.5% among cases [30]. Each subject gave written informed consent. The study was approved by the Institutional Review Board of the French National Institute of Health and Medical Research (IRB-Inserm,

Study sample

n° 01-036), and by the French Data Protection Authority (CNIL n° 90120).

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Only women were considered in this analysis. In all, 361 female head and neck cancer cases were included in the ICARE study. The present analysis was restricted to squamous cell carcinomas of the following cancer sites: i) oral cavity, 88 cases (29.7%): ICD-O-3 codes C00.3 – C00.9, C02.0 – C02.3, C03, C04, C05.0 and C06; ii) oropharynx, 111 cases (37.5%): codes C01.9, C02.4, C05.1, C05.2, C09 and C10; iii) hypopharynx, 28 cases (9.5%): codes C12-C13; iv) oral cavity, pharynx unspecified or overlapping, 22 cases (7.4%): codes C02.8, C02.9, C05.8, C05.9 and C14; v) larynx, 47 cases (15.9%): codes C32. There were 296 cases and 775 controls in the final study group.

Coding of job titles

Each job held for at least one month was coded using the International Standard Classification of Occupations (ISCO) [31] and the Nomenclature des Activités Françaises (NAF) [32], the French classification for industrial activities. Occupational histories were coded by specially trained coders blind as to the case-control status.

BMJ Open

Exposure assessment

Occupational exposure to five chlorinated solvents (carbon tetrachloride; chloroform; methylene chloride; perchloroethylene; trichloroethylene), five petroleum solvents (benzene; special petroleum product; gasoline; white-spirits and other light aromatic mixtures; diesel, fuels and kerosene) and five oxygenated solvents (alcohols; ketones and esters; ethylene glycol; diethyl ether; tetrahydrofuran) was assessed using job-exposure matrices (JEMs) developed for the French population by the French Institute of Health Surveillance [33]. For each combination of ISCO and NAF codes, the JEMs assigned three exposure indices: (*i*) probability of exposure expressed as the percentage of exposed workers (*ii*) intensity of exposure and (*iii*) frequency of exposure. For these three indices, different categories were used depending on the solvent considered (See Supplementary material: Table S-I).

To account for changes in exposure over time, different indices were provided for different calendar periods from 1947 to 2007. Exposure information for the earliest period was used for jobs held before 1947.

'Ever exposed' to a specific solvent refers to subjects having had at least one job with probability of exposure greater than zero. Cumulative duration of exposure was computed by summing all exposed periods.

Cumulative Exposure Indices (CEIs) were obtained by summing the product of exposure probability, frequency, intensity and duration for each job period, over the lifetime occupational history, using the central value of each of the three classes. We also calculated the average exposure intensity, as the CEI divided by the total duration of exposure.

Statistical analysis

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Exposure duration, average exposure intensity and CEI were used as continuous variables. We first used restricted cubic splines (4 knots) to check the linearity assumption. None of the tests for departure from linearity were significant. Exposure variables were also categorized (cutpoints: 10 years for duration, median of the distributions among controls for average intensity and CEI). In all analyses, 'never exposed' refers to subjects never exposed to a specific solvent and was used as the reference category.

Because of the low exposure prevalence for most solvents among women, we favored sensitivity over specificity by using a broad definition of ever exposure (probability >0). We also conducted additional analyses using different cut-off points for probability, in order to increase specificity.

Unconditional logistic regression was used to estimate odds ratios (ORs) and corresponding 95% confidence intervals (95% CI) of head and neck cancers. Analyses were adjusted for geographic area (ten "départements"), age, smoking status (never smoker, former smoker and current smoker), tobacco consumption in pack-years, and alcohol consumption in drinkyears. Cubic splines were used for alcohol and tobacco because they allowed to better take into account their effects, according to the Bayesian information criterion. Since interactions between smoking status and alcohol consumption, and between smoking status and tobacco consumption, were significant, all models included these interaction terms.

Additional adjustments were made for socioeconomic status (SES) assessed by the last occupation held and by the longest held occupation. Since additional adjustment for SES did not markedly change the results, while it increased the number of parameters to be estimated, the odds ratios reported in the results section are those not adjusted for SES. Adjustment for asbestos exposure was also performed but did not modify the estimates and these results are not presented here.

BMJ Open

ORs were also estimated for each cancer site (as described above: oral cavity, oropharynx, hypopharynx and larynx) using polytomous logistic regression.

Statistical analyses were performed using STATA software (StataCorp LP 2015; V. 13.1). All p values were two-sided and a p value ≤0.05 was used as a threshold for statistical significance.

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Results

The main characteristics of cases and controls are presented in Table I. On average, cases were 2 years younger than controls. This is explained by the fact that controls were stratified on age (in four categories: less than 40 years, 40-54 years, 55-64 years and >65 years) based on the age distribution of both head and neck cancer cases and lung cancer cases. The socioeconomic status of cases was lower than that of controls. Cases were less likely to be never smokers or never drinkers than controls. Table II shows the numbers and proportions of cases and controls exposed to the various chlorinated, petroleum and oxygenated solvents. The prevalence of exposure was low (10% or less among controls) for most of the specific solvents, with the exception of white-spirits and alcohols, for which respectively 32% and 48% of the controls were exposed.

Ever exposure to trichloroethylene and to perchloroethylene was associated with significantly elevated ORs. No other significant association was found. Additional analyses using a more specific cutpoint to define ever exposure (probability > 10% for methylene chloride, probability>30% for trichloroethylene, probability > 50% for the other solvents) produced similar results, although the confidence intervals were wider due to the smaller number of exposed women (data not shown).

The number of women ever exposed to chloroform, carbon tetrachloride, motor gasoline, ethylene glycol and tetrahydrofuran was very low; for this reason, these five solvents were excluded from further analyses. Associations between head and neck cancer risk and other exposure variables are given in Table III.

Chlorinated solvents

The risk of head and neck cancer increased with the duration of exposure to trichloroethylene (Table III). A similar increase in risk with duration of exposure was found

BMJ Open

for exposure to perchloroethylene. No clear relationship was observed between head and neck cancer and average intensity or cumulative exposure to trichloroethylene in the categorical analysis, the highest ORs being observed in the lowest cumulative exposure category. However, when average intensity and CEI were considered as continuous variables, significant trends were observed for both. On the other hand, for perchloroethylene, average intensity and cumulative exposure were not associated with head and neck cancer.

The distribution of job periods exposed to trichloroethylene by occupation (See Supplementary material: Figure 1) shows that the most frequently exposed occupations were shoes and leather workers, dry cleaners and launderers, rubber and plastics workers, welders and electronics workers. The most frequent sector of activity exposed to trichloroethylene was the leather and footwear industry.

Since leather workers may have also been exposed to benzene in the past, we also estimated mutually adjusted ORs for the association between head and neck cancer and exposure to trichloroethylene and benzene. The OR for trichloroethylene remained significantly elevated (OR=2.05, 95% Cl 1.04 to 4.01) whereas no association with benzene exposure was found (OR=1.11, 95% Cl 0.52 to 2.36).

The distribution of job periods exposed to perchloroethylene by occupation (See Supplementary material: Figure 2) shows that the most frequently exposed occupations were dry cleaners launderers, degreasers, assemblers in electrical and electronic equipment. The most frequent sector of activity was laundry and dry cleaning.

Exposures to trichloroethylene and perchloroethylene were strongly correlated, and were also correlated to methylene chloride exposure, which makes the interpretation of mutually adjusted ORs difficult. Instead, we studied exposure to exclusive combinations of

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

chlorinated solvents (Table IV). No case was exposed only to perchloroethylene. The odds ratio associated with trichloroethylene alone was high (OR=1.81, 95% CI 0.81 to 4.04), but lower than in the analysis reported in Table II (OR=2.15, 95% CI 1.21 to 3.81). Exposure to methylene chloride alone was associated with an OR lower than 1 (OR=0.50, 95% CI 0.11 to 2.18). A high OR was associated with joint exposure to trichloroethylene and perchloroethylene (OR=4.47, 95% CI 1.27 to 15.8).

Analyses by cancer sites are presented in Table V. The OR associated with trichloroethylene exposure was elevated for larynx (OR=3.80, 95%Cl 1.55 to 9.32) and oral cavity (OR=2.12, 95%Cl 0.97 to 4.60), the latter showing a dose-response relation with duration and cumulative exposure (See Supplementary material: Table S-II, OR=6.84, 95%Cl 2.11 to 22.1 for duration > 10 years; OR=2.73, 95%Cl 1.02 to 7.30 for CEl > median). There was also a suggestion of an increase in laryngeal cancer risk by duration of exposure. Perchloroethylene exposure was associated with an increased risk of laryngeal (OR=7.95, 95%Cl 1.92 to 32.9) and oropharyngeal cancers (OR=3.43, 95%Cl 1.01 to 11.8). The small numbers of exposed cases made it difficult to study dose-response relationships.

Petroleum solvents

The study of the association between head and neck cancer and exposure to petroleum solvents (Table II) showed slight, non significant elevations in risk for benzene (OR=1.65, 95% CI 0.87 to 3.13), diesel (OR=1.79, 95% CI 0.75 to 4.29) and special petroleum products (OR=1.40, 95% CI 0.74 to 2.65). No dose-response relationship was found with the duration of exposure, with the average intensity or with CEI (Table III). Exposure to white-spirit (Table V) was associated with a non-significantly increased risk of oral cavity cancer (OR=1.54, 95% CI 0.90 to 2.66), which increased with CEI (OR=1.20, 95% CI 0.56 to 2.54 for CEI < median; OR=1.75, 95% CI 0.91 to 3.37 for CEI > median) and duration of exposure (OR=0.97, 95% CI

BMJ Open

0.48 to 1.96 for < 10 years; OR=2.51, 95% CI 1.25 to 5.02 for 10 years or more) (See Supplementary material: Table S-III)

Oxygenated solvents

With regards to oxygenated solvents (Table II), no elevated risks were associated with diethyl ether (OR=0.65, 95% CI 0.36 to 1.19) or alcohols (OR=0.83, 95% CI 0.57 to 1.20) exposure. An elevated but not significant OR (OR=1.61, 95% CI 0.96 to 2.70) was associated with ketones exposure but without dose-response relationship with duration of exposure, average intensity or CEI (Table III). The OR associated with ever exposure to ketones was significantly elevated for laryngeal cancer (OR=2.66, 95% CI 1.17 to 6.07) but there was no CL. increase in risk with duration of exposure or CEI (See Supplementary material: Table S-IV).

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Discussion

We studied occupational exposures to chlorinated, petroleum and oxygenated solvents in relation to head and neck cancer risk in women in France. Some solvent exposures associated with an increased risk of cancer in women have been identified, notably exposure to trichloroethylene and perchloroethylene, with high and significant risks. For trichloroethylene a clear and significant duration-response relationship was found and there was also some evidence of an increase in risk with intensity and cumulative exposure. For perchloroethylene however, the increase in risk with duration was not significant and there was no indication of a dose-response relation with intensity or cumulative exposure. Risks associated with other solvents were sometimes slightly elevated but not significantly so, or without a duration-response relationship.

Trichloroethylene (TCE) is one of the most commonly used chlorinated solvents. It has been used as a metal degreasing product and was also widely used for manually degreasing textiles, or cleaning machinery and equipment when applying paints, glues, adhesives, plastics, rubbers, etc. TCE was recently classified as *carcinogenic to humans* (Group 1) based on sufficient epidemiological evidence for cancer of the kidney. Most of the information on the association between TCE and cancer risk derives from cohort studies which include only a small number of head and neck cancers, especially among women, and sometimes do not report results for these cancer sites. Wartenberg et al. [34] reviewed data on exposure to TCE and cancer in a meta-analysis. They concluded that there was a weak suggestion of an increased risk of laryngeal cancer, and on average no evidence of an association with oral and pharyngeal cancer, despite substantial heterogeneity between studies. More recently, Raaschou-Nielsen [35] found SIRs of 1.8 for buccal cavity and pharynx cancers (10 observed) and 1.7 for larynx cancers (3 observed) in women exposed to TCE in a Danish cohort study

Page 17 of 42

BMJ Open

including more than 340 companies with documented use of TCE. Interestingly, the SIRs among men were lower, around 1.1 to 1.2. Boice et al. [36] reported not significantly elevated SMR for buccal cavity and pharynx cancers (4 observed) and for larynx cancers (2 observed) among men exposed to TCE in a rocket engine testing facility. In 2013, Hansen et al. [37] established a pooled cohort including 5553 workers with well documented individual exposure to TCE in Finland, Sweden and Denmark. They observed a SIR for buccal and pharyngeal cancers of 1.71 (95% CI 0.74 to 3.38) and 2.94 (95% CI 0.36 to 10.6) respectively among men (8 observed) and among women (2 observed). For laryngeal cancers, the SIR was 1.46 (95% CI 0.72 to 2.61) in men (11 observed) and no case was observed in women. In a cohort of aircraft maintenance workers [38] a non-significantly increased risk of oral and pharyngeal cancer was observed for workers exposed vs not exposed to TCE among men (11 exposed cases, OR=1.23, 95% CI 0.34 to 4.43) and among women (2 exposed cases, OR=1.08, 95% CI 0.18 to 6.47), but no gradient with cumulative exposure was apparent. Overall, several studies of workers exposed to TCE have reported elevated but not statistically significant relative risks for oral, pharyngeal and/or laryngeal cancer, but the small number of cases and the lack of data on confounding factors make interpretation difficult. Our finding of a significantly increased risk of head and neck cancer associated with TCE exposure, based on a case-control study with larger numbers of exposed cases and with thorough adjustment for alcohol and tobacco consumption is globally consistent with the literature. We also observed a duration-response relationship. Concerning cumulative exposure, our results are less conclusive, with similar ORs below and above the median, but a globally significant trend with CEI. The increase in risk associated with TCE was larger for laryngeal cancer (OR=3.80, 95% CI 1.55 to 9.32), and somewhat smaller for cancer of the oral cavity (OR=2.12, 95% CI 0.97 to 4.60).

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Since the 1950s, perchloroethylene (PCE), another widely used chlorinated solvent, was used extensively in dry cleaning but also for metal degreasing and for cleaning machinery and equipment. IARC classified PCE as probably carcinogenic to humans [25]. Since the 1990s, its use has been more limited, particularly for metal degreasing, but it continues to be used for dry degreasing of clothes, albeit under stricter conditions. The literature on the risks of head and neck cancers related to exposure to PCE is very limited. Mundt et al. [39] reviewed the risk of cancer linked to PCE exposure. They concluded that the possibility of an association between oral, pharyngeal and laryngeal cancer and PCE appeared unlikely. In a cohort of dry cleaners, a significantly elevated SMR was observed for laryngeal cancer among workers with the highest estimated level of exposure to dry cleaning solvents, primarily PCE [40]. Deaths from cancer of the buccal cavity and pharynx were not in excess in this cohort. In another cohort of dry cleaners, exposure to PCE was found to be associated with a significant increase in tongue cancer, but not in laryngeal cancer [41]. As for TCE, these findings rely on small numbers of cases, and information on confounding factors was not available. A case-control study showed a high, although not significant, OR associated with exposure to PCE, after adjustment for alcohol and tobacco consumption [42]. In another case-control study, in which smoking and alcohol drinking were controlled for, a significantly increased risk of laryngeal cancer was also found to be associated with exposure to chlorinated solvents, but information on specific solvents was not available [24]. In line with these results, we observed elevated ORs for laryngeal cancers in relation with PCE (4 exposed cases, OR=7.95, 95% CI 1.92 to 32.9).

In our study, it is not possible to distinguish precisely the risks associated with TCE from those associated with PCE. Indeed, no woman in our study was exposed only to PCE. However, the study of combinations of exposures to different chlorinated solvents suggests

BMJ Open

that the risk for joint exposure to both TCE and PCE (9 exposed cases, OR=4.47, 95% CI 1.27 to 15.8) is higher than for exposure to TCE only (20 exposed cases, OR=1.81, 95% CI 0.81 to 4.04).

Overall, our results are consistent with an effect of occupational exposure to these two chlorinated solvents on the occurrence of head and neck cancers, particularly with laryngeal cancer. Among men in the ICARE study [43], there was also an increased risk of laryngeal cancer associated with high levels of exposure to PCE. However, no association was found between head and neck cancer and exposure to TCE in men, after adjustment for asbestos exposure. This difference in results between men and women is probably due to confounding by asbestos. In women, jobs involving exposure to TCE, mainly related to leather work or dry cleaning, are unlikely to entail exposure to asbestos, and actually adjusting for asbestos had no or very limited effect on the risk related to TCE in women. In men, the stronger correlation between asbestos and TCE exposure made it difficult to study an independent role of TCE. Another possible explanation is that there are true gender differences in risk. Some studies, although based on very small numbers, have suggested higher relative risks in women than in men, and gender differences in the toxicokinetics of TCE have been reported [28, 29, 44].

Petroleum solvents, and even more so oxygenated solvents, are also widely used by women in the workplace. Overall, our results do not provide evidence of a substantial role of these solvents in head and neck cancer etiology. However, we found a significantly increased risk of cancer of the oral cavity among women exposed for more than 10 years to white spirits, as well as a significantly increased risk of laryngeal cancer associated with exposure to ketones. To our knowledge, these associations have not be examined previously. Although these findings may be due to chance, they warrant further investigation.

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

One strength of our study is that it included almost 300 female incident cases of well characterized HNSCC. This makes it one of the largest case-control studies in women. The design of ICARE was population-based; cases were incident and were identified by qualified cancer registries in 10 French geographical areas. It was verified that the distribution of the main occupational and economic activity characteristics of the active population in these regions was similar to their distribution in France [30]. Participation rates were satisfactory for a population-based case-control study [30]. The control group was a random sample of the population of these areas and the distribution of socioeconomic characteristics was also similar to their distribution in the general population. Moreover, lifelong exposure prevalences among women controls were of the same order of magnitude as those estimated among women in the general population for the solvents under study [33]. Distribution by age, sex and cancer site of the head and neck cancer cases included in ICARE was similar to that observed for head and neck cancer cases in all of France. Thus, selection bias is unlikely, and was probably marginal if it occurred at all.

Our study has some limitations. Despite a relatively large number of cases, statistical power was limited for in-depth analyses by cancer sites. Because this is a case-control study, recall bias is possible. However, it should be very limited since the number of jobs reported by cases and controls was similar (on average 3.3 for cases and 3.7 for controls). Although occupations and industries are self-reported, it is unlikely that this bias would be differential between cases and controls because occupational exposures are not widely known to be risk factors for head and neck cancers, particularly among women. Coding occupation and industry is difficult and often not reproducible. However, coders received special training and were blind as to case-control status. If coding errors were made, they were therefore not differential. Residual confounding is always a possibility. But we took into account age,

BMJ Open

alcohol and tobacco consumption, the interaction between alcohol and tobacco, and socioeconomic status. Special attention was paid to adjustment for alcohol and tobacco consumption, with the use of cubic splines allowing to better account for the effect of these two confounding factors. Therefore, residual confounding in relation with alcohol and tobacco consumption is unlikely to be a major problem in this study. However, other known or suspected risk factors such as nutritional factors or HPV infection were not considered in this analysis but it is unlikely that they explain the observed associations.

Another limitation of our study is that this type of JEM-analysis, based on job-specific averages, do not achieve a high level of accuracy in the exposure assessment [45]. The use of JEMs may produce misclassification of exposure, which is likely to be independent of case-control status. Non-differential misclassification bias results in an estimation of the odds ratio biased towards 1, with an associated loss of statistical power for dichotomized exposures, [46] but may also distort exposure-response trends in multilevel exposure analyses[47]. In our categorical analyses for TCE and PCE, we found duration-response relationships, but no dose-response relation with intensity, and consequently no doseresponse relation with cumulative exposure. Assessment of exposure levels is more prone to error than duration, so misclassification could partly explain our findings. Furthermore, the JEMs used are not gender-specific. The construction of the JEMs [33] was based primarily on knowledge acquired from men, and misclassification may be more frequent among women. However, this type of bias cannot explain positive findings.

Finally, we assessed a large number of associations, and multiple comparisons may be an issue. Instead of applying an overly conservative adjustment, we chose to rely on the consistency of results between the different exposure variables, as well as on published results, to draw our conclusions [48, 49].

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

<text> In conclusion, our findings suggest that the exposure to TCE and PCE may increase the risk of HNSCC; in contrast, there is no clear evidence that the other solvents studied are risk factors for HNSCC. Nevertheless, further investigations are necessary to replicate these results in a larger, exposed female population.

BMJ Open

Acknowledgements

The ICARE study was funded by the French National Research Agency (ANR); French National Cancer Institute (INCA); French Agency for Food, Environmental and Occupational Health and Safety (ANSES); French Institute for Public Health Surveillance (InVS); Fondation pour la Recherche Médicale (FRM); Fondation de France; Association pour la Recherche sur le Cancer (ARC); Ministry of Labour (Direction Générale du Travail); Ministry of Health (Direction Générale de la Santé).

The present work was supported by a grant from the "Fondation ARC pour la recherche sur le cancer".

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

1		
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11	1	Ferlay
12	-	i criay
13		
14	2	Binde
15	2	Diffue
16		
17	-	c
18	3	Secret
19		
20		
21	4	Hashil
22		
23		
24		
25		
26	5	Boffet
27	-	
28		
29	6	Boffet
30	0	Donet
31		
32		
33	_	
34	7	Browr
35		
36		
37	8	De Ste
38		
39		
40	9	Dietz /
41		
42		
43		
44	10	Goldb
45	10	001010
46		
40	11	Merle
48	11	wiche
40		
49 50	10	N 4
50	12	Musca
52 53		
	13	Paget
54 55		
55		
56		
57		
58		
59		
60		

Reference List

- / J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46 (4):765-81.
- r-Foucard F, Bossard N, Delafosse P, et al. Cancer incidence and mortality in France over the 1980-2012 period: solid tumors. *Rev Epidemiol Sante Publique* 2014;62 (2):95-108.
- tan B, Straif K, Baan R, et al. A review of human carcinogens--Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009;10 (11):1033-4.
- be M, Brennan P, Chuang SC, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009;18 (2):541-50.
- tta P, Gridley G, Gustavsson P, et al. Employment as butcher and cancer risk in a recordlinkage study from Sweden. Cancer Causes Control 2000;11 (7):627-33.
- tta P, Richiardi L, Berrino F, et al. Occupation and larynx and hypopharynx cancer: an international case-control study in France, Italy, Spain, and Switzerland. Cancer Causes *Control* 2003;**14** (3):203-12.
- n LM, Mason TJ, Pickle LW, et al. Occupational risk factors for laryngeal cancer on the Texas Gulf Coast. Cancer Res 1988;48 (7):1960-4.
- efani E, Boffetta P, Oreggia F, et al. Occupation and the risk of laryngeal cancer in Uruguay. Am J Ind Med 1998;33 (6):537-42.
- A, Ramroth H, Urban T, et al. Exposure to cement dust, related occupational groups and laryngeal cancer risk: results of a population based case-control study. Int J Cancer 2004;**108** (6):907-11.
- erg P, Leclerc A, Luce D, et al. Laryngeal and hypopharyngeal cancer and occupation: results of a case control-study. Occup Environ Med 1997;54 (7):477-82.
- etti F, Boffetta P, Ferro G, et al. Occupation and cancer of the oral cavity or oropharynx in Turin, Italy. Scand J Work Environ Health 1991;17 (4):248-54.
- at JE, Wynder EL. Tobacco, alcohol, asbestos, and occupational risk factors for laryngeal cancer. Cancer 1992;69 (9):2244-51.
- -Bailly S, Guida F, Carton M, et al. Occupation and Head and Neck Cancer Risk in Men: Results From the ICARE Study, a French Population-Based Case-Control Study. J Occup Environ Med 2013.

1 2 3 4		
5 6		
7 8 9 10		
11 12 13		
14 15 16		
17 18 19		
20 21 22 23		
24 25 26		
27 28 29		
30 31 32		
33 34 35 36		
37 38 39		
40 41 42		
43 44 45		
46 47 48 49		
50 51 52		
53 54 55		
56 57 58		
59 60		

14 Richiardi L, Corbin M, Marron M, *et al.* Occupation and risk of upper aerodigestive tract cancer: the ARCAGE study. *Int J Cancer* 2012;**130** (10):2397-406.

- 15 Schildt EB, Eriksson M, Hardell L, *et al.* Occupational exposures as risk factors for oral cancer evaluated in a Swedish case-control study. *Oncol Rep* 1999;**6** (2):317-20.
- 16 Wortley P, Vaughan TL, Davis S, et al. A case-control study of occupational risk factors for laryngeal cancer. Br J Ind Med 1992;49 (12):837-44.
- 17 Zagraniski RT, Kelsey JL, Walter SD. Occupational risk factors for laryngeal carcinoma: Connecticut, 1975-1980. *Am J Epidemiol* 1986;**124** (1):67-76.
- 18 Czene K, Tiikkaja S, Hemminki K. Cancer risks in hairdressers: assessment of carcinogenicity of hair dyes and gels. *Int J Cancer* 2003;**105** (1):108-12.
- 19 Huebner WW, Schoenberg JB, Kelsey JL, *et al.* Oral and pharyngeal cancer and occupation: a case-control study. *Epidemiology* 1992;**3** (4):300-9.
- 20 Ji J, Hemminki K. Occupation and upper aerodigestive tract cancers: a follow-up study in Sweden. J Occup Environ Med 2005;47 (8):785-95.
- 21 Pukkala E, Martinsen JI, Lynge E, *et al.* Occupation and cancer follow-up of 15 million people in five Nordic countries. *Acta Oncol* 2009;**48** (5):646-790.
- 22 Carton M, Guida F, Paget-Bailly S, *et al.* Occupation and head and neck cancer in women-Results of the ICARE study. *Am J Ind Med* 2014;**57** (12):1386-97.
- 23 Berrino F, Richiardi L, Boffetta P, et al. Occupation and larynx and hypopharynx cancer: a jobexposure matrix approach in an international case-control study in France, Italy, Spain and Switzerland. Cancer Causes Control 2003;14 (3):213-23.
- 24 Shangina O, Brennan P, Szeszenia-Dabrowska N, et al. Occupational exposure and laryngeal and hypopharyngeal cancer risk in central and eastern Europe. Am J Epidemiol 2006;**164** (4):367-75.
- 25 IARC. TRICHLOROETHYLENE, TETRACHLOROETHYLENE, AND SOME OTHER CHLORINATED AGENTS. *IARC Monogr Eval Carcinog Risks Hum* 2014;**106**:1-512.
- 26 Cogliano VJ, Baan R, Straif K. Updating IARC's carcinogenicity assessment of benzene. *Am J Ind Med* 2011;**54** (2):165-7.
- 27 Dananché B. Présentation de matrices emplois-expositions à cinq solvants chlorés. Quelques applications à un échantillon de population en France. Institut de veille sanitaire 2009.
- 28 Fisher JW, Mahle D, Abbas R. A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. *Toxicol Appl Pharmacol* 1998;**152** (2):339-59.
- 29 Sato A. Confounding factors in biological monitoring of exposure to organic solvents. *Int Arch Occup Environ Health* 1993;**65** (1 Suppl):S61-S67.

30 Luce D, Stucker I, Icare Study Group. Investigation of occupational and environmental causes of respiratory cancers (ICARE): a multicenter, population-based case-control study in France. *BMC Public Health* 2011;**11** (1):928.

- 31 International Labour Office. International Standard Classification of Occupations. Geneva (Switzerland) 1968.
- 32 Institut National de la Statistique et des Etudes Economiques. Nomenclature des Activités Françaises, Révision 1. France 2000.
- 33 Fevotte J, Dananche B, Delabre L, *et al.* Matgene: a program to develop job-exposure matrices in the general population in France. *Ann Occup Hyg* 2011;**55** (8):865-78.
- 34 Wartenberg D, Reyner D, Scott CS. Trichloroethylene and cancer: epidemiologic evidence. *Environ Health Perspect* 2000;**108 Suppl 2**:161-76.
- 35 Raaschou-Nielsen O, Hansen J, McLaughlin JK, et al. Cancer risk among workers at Danish companies using trichloroethylene: a cohort study. Am J Epidemiol 2003;158 (12):1182-92.
- 36 Boice JD, Jr., Marano DE, Cohen SS, *et al.* Mortality among Rocketdyne workers who tested rocket engines, 1948-1999. *J Occup Environ Med* 2006;**48** (10):1070-92.
- Hansen J, Sallmen M, Selden AI, et al. Risk of cancer among workers exposed to trichloroethylene: analysis of three Nordic cohort studies. J Natl Cancer Inst 2013;105 (12):869-77.
- 38 Radican L, Blair A, Stewart P, et al. Mortality of aircraft maintenance workers exposed to trichloroethylene and other hydrocarbons and chemicals: extended follow-up. J Occup Environ Med 2008;50 (11):1306-19.
- 39 Mundt KA, Birk T, Burch MT. Critical review of the epidemiological literature on occupational exposure to perchloroethylene and cancer. Int Arch Occup Environ Health 2003;76 (7):473-91.
- 40 Blair A, Petralia SA, Stewart PA. Extended mortality follow-up of a cohort of dry cleaners. Ann Epidemiol 2003;13 (1):50-6.
- 41 Calvert GM, Ruder AM, Petersen MR. Mortality and end-stage renal disease incidence among dry cleaning workers. *Occup Environ Med* 2011;**68** (10):709-16.
- 42 Vaughan TL, Stewart PA, Davis S, *et al.* Work in dry cleaning and the incidence of cancer of the oral cavity, larynx, and oesophagus. *Occup Environ Med* 1997;**54** (9):692-5.
- 43 Fayossé A, Menvielle G, Cyr D, et al. Head and neck cancer and occupational exposure to chlorinated solvents: results from the ICARE study. Occupational and Environmental Medicine 2014;71 (Suppl 1):A99-A100.
- 44 Rusyn I, Chiu WA, Lash LH, *et al.* Trichloroethylene: Mechanistic, epidemiologic and other supporting evidence of carcinogenic hazard. *Pharmacol Ther* 2014;**141** (1):55-68.

- 45 Stengel B, Pisani P, Limasset JC, *et al.* Retrospective evaluation of occupational exposure to organic solvents: questionnaire and job exposure matrix. *Int J Epidemiol* 1993;**22 Suppl** 2:S72-S82.
- 46 Bouyer J, Dardenne J, Hemon D. Performance of odds ratios obtained with a job-exposure matrix and individual exposure assessment with special reference to misclassification errors. *Scand J Work Environ Health* 1995;**21** (4):265-71.
- 47 Dosemeci M, Wacholder S, Lubin JH. Does nondifferential misclassification of exposure always bias a true effect toward the null value? *Am J Epidemiol* 1990;**132** (4):746-8.
- 48 Goldberg M, Silbergeld E. On multiple comparisons and on the design and interpretation of epidemiological studies of many associations. *Environ Res* 2011;**111** (8):1007-9.
- djustments . Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1

Table I: Main characteristics of cases and controls

		Cases	(Controls
	n	%	n	%
Département				p=0.003
Calvados	23	7.8	104	13.4
Doubs+ Territoire de Belfort	1	0.3	31	4.0
Hérault	44	14.9	90	11.6
lsère	37	12.5	94	12.1
Loire Atlantique	38	12.8	93	12.0
Manche	37	12.5	65	8.4
Bas-Rhin	33	11.2	109	14.1
Haut-Rhin	9	3.0	29	3.7
Somme	54	18.2	112	14.5
Vendée	20	6.8	48	6.2
Age at interview, years				p<0.0001
Mean (95%CI)	58.0 (56.	9-59.0)	60.4 (59.	6-61.2)
Class				
<50 years	51	17.2	160	20.6
50-59.9 years	109	36.8	157	20.3
60-69.9 years	99	33.4	246	31.8
≥ 70 years	37	12.6	212	27.3
Number of jobs held				p=0.01
Mean (95%Cl)	3.3 (2.9-3.6	5)	3.7 (3.4-3.8	3)
Range	18		13	
Socioeconomic status (the longest dur	ation)			p=0.001
Farmers	3	1.1	29	. 3.8
Self-employed workers	14	5.1	25	3.3
Managers	19	6.9	74	9.7
Intermediate white-collar workers	28	10.1	131	17.3
Office and sales employees	150	54.1	375	49.4
Blue-collar workers	63	22.7	125	16.5
Missing	19		16	-
Smoking	-		-	p<0.0001
Never*	60	20.3	509	66.1
Former smokers#	46	15.5	134	17.4
Current smokers	190	64.2	127	16.5
Missing	-	0	5	2010
Pack-Years (Former and current)			3	p<0.0001
<6.89	23	9.9	100	38.5
6.9-19.9	34	14.6	87	33.5
20.0-35.24	78	33.5	47	18.1
≥35.25	98	42.1	26	10.1
Missing	3	72.1	20	-
Drinking (drink-years)	5	-	0	
	<u>л</u> л	15 4	177	p<0.0001
Never	44	15.4	177	22.9
< 2.79	39 25	13.6	173	22.4
2.8-16.3	35	12.2	172	22.3
16.4-64.9	51	17.8	155	20.0
≥ 65.0	117	40.9	96	12.4

*: Nonsmokers were subjects who had smoked fewer than 100 cigarettes or equivalent in their lifetime

#: Former smokers were subjects who had stopped smoking at least 2 years before diagnosis (cases)/interview (controls).

BMJ Open

Table II: Association between head and neck cancer and ever exposure to solvents

4			Never	exposed			Ever e				
5		С	ases	Cor	ntrols	Ca	ises	Cor	ntrols	(OR#
6		n	%	n	%	n	%	n	%		
7	Chloroform	272	98,2	748	98,7	5	1.8	10	1.3	0.36	0.09 to 1.49
8	Carbon tetrachloride	271	97,9	746	98,4	6	2.1	12	1.6	0.36	0.09 to 1.55
9	Methylene chloride	264	95,1	728	96,1	14	4.9	30	3.9	1.09	0.46 to 2.57
10	Trichloroethylene	240	86,6	697	92,2	38	13.4	60	7.8	2.15	1.21 to 3.81
11	Perchloroethylene	268	96,5	744	98,3	10	3.5	13	1.7	2.97	1.05 to 8.45
12	Motors gasoline	273	98,6	748	98,8	4	1.4	9	1.2	1.54	0.36 to 6.63
13	Special petroleum product	251	90,5	705	93	27	9.5	54	7.0	1.40	0.74 to 2.65
	Diesel	264	95,1	731	96,6	14	4.9	26	3.4	1.79	0.75 to 4.29
14	Benzene	250	90,1	709	93,5	28	9.9	50	6.5	1.65	0.87 to 3.13
15	White-spirits	188	68,3	513	67,8	87	31.7	247	32.2	1.08	0.73 to 1.60
16	Ethylene glycol	276	99,6	752	99,3	1	0.4	5	0.7	1.75	0.17 to 18.4
17	Tetrahydrofurane	273	98,6	754	99,6	4	1.4	3	0.4	4.97	0.86 to 28.8
18	Diethyl ether	252	91,2	669	88,5	25	8.8	88	11.5	0.65	0.36 to 1.19
19	Ketones	234	84,5	675	89,2	44	15.5	83	10.8	1.61	0.96 to 2.70
20	Alcohols	152	55,6	394	52,4	123	44.4	364	47.6	0.83	0.57 to 1.20
21	# OR adjusted for age at interview, de	epartment, al	cohol and tobac	co consumptio	n.						
22											
23											
24											
25											
26											
20 27											
28											
29											
30											
31											0.57 to 1.20
32											
33											
34											
35											

BAU Open: first published as 10.1136/bmjopen-2012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

Table III: Association between head and neck cancer and exposure to selected solvents

	Never Exposed	D	Duration of exposure		,	Mean intensity level		Cun	nulative Exposure Index	
		< 10 years	≥ 10 years	Continuous	< median	≥ median	Continuous	< median	≥ median	Continuous
	OR [#] 95% CI Ca	Co OR [#] 95% Cl	Ca Co OR [#] 95% CI	OR [#] 95% CI	Ca Co OR [#] 95% CI	Ca Co OR [#] 95% Cl	OR [#] 95% CI	Ca Co OR [#] 95% Cl	Ca Co OR [#] 95% Cl	OR [#] 95% CI
Chlorinated solvents										
Methylene chloride	1 Ref. 7	21 0.85 0.28-2.56	7 9 1.65 0.42-6.53	0.99 0.93-1.05	4 19 0.62 0.18-2.16	10 11 2.02 0.60-6.84	1.23 0.77-1.97	7 15 1.34 0.42-4.28	7 15 0.87 0.25-2.99	1.01 0.97-1.06
Trichloroethylene	1 Ref. 25	47 1.67 0.86-3.24	13 13 4.44 1.56-12.6	5 1.06 1.01-1.12	24 30 2.62 1.24-5.54	14 30 1.67 0.71-3.90	1.30 1.01-1.66	20 30 2.16 1.02-4.58	18 30 2.13 0.94-4.84	1.02 1.01-1.04
Perchloroethylene	1 Ref. 8	9 2.66 0.75-9.40	2 4 3.75 0.64-21.9	1.06 0.97-1.17	4 7 3.56 0.90-14.1	6 62.38 0.51-11.2	1.08 0.95-1.23	8 7 4.09 1.15-14.6	2 6 1.44 0.18-11.6	1.00 0.99-1.02
Petroleum solvents										
Special petroleum product	1 Ref. 19	30 1.47 0.67-3.20	8 24 1.30 0.47-3.65	6 0.99 0.94-1.04	18 27 1.30 0.56-3.01	9 27 1.54 0.61-3.89	1.01 0.93-1.11	21 27 1.51 0.68-3.35	6 27 1.25 0.45-3.45	1.00 0.99-1.01
Diesel	1 Ref. 12	16 2.89 1.03-8.08	2 10 0.56 0.09-3.31	1.02 0.95-1.10	8 14 1.56 0.49-4.97	6 12 2.13 0.59-7.61	1.30 0.94-1.78	6 12 1.14 0.31-4.29	8 14 2.52 0.82-7.74	1.00 0.97-1.03
Benzene	1 Ref. 21	35 1.77 0.85-3.67	7 15 1.34 0.38-4.68	3 1.00 0.94-1.06	20 28 1.52 0.67-3.43	8 22 1.87 0.71-4.96	1.38 0.36-5.22	19 25 1.59 0.69-3.64	9 25 1.74 0.67-4.53	1.02 0.89-1.17
White-spirits	1 Ref. 50	153 0.87 0.54-1.40	37 94 1.45 0.83-2.52	1.01 0.99-1.04	62 182 1.08 0.70-1.67	25 64 0.96 0.49-1.86	0.94 0.74-1.20	42 118 1.04 0.62-1.74	45 129 1.08 0.65-1.78	1.00 0.98-1.02
Oxygenated solvents										
Diethyl ether	1 Ref. 9	25 1.07 0.39-2.91	16 63 0.52 0.25-1.07	0.98 0.95-1.01	12 44 0.58 0.25-1.33	13 44 0.73 0.32-1.67	0.01 0.00-326	13 44 0.89 0.41-1.95	12 44 0.46 0.19-1.10	0.70 0.41-1.27
Ketones	1 Ref. 32	55 1.71 0.94-3.11	12 28 1.42 0.58-3.48	8 1.02 0.98-1.06	22 42 1.68 0.81-3.46	22 41 1.56 0.79-3.06	1.11 0.92-1.35	28 42 2.27 1.16-4.44	16 41 1.10 0.52-2.31	1.01 0.99-1.02
Alcohols	1 Ref. 67	168 0.93 0.59-1.45	56 196 0.71 0.44-1.13	0.99 0.97-1.01	80 255 0.76 0.50-1.15	43 109 0.89 0.53-1.51	1.33 0.90-1.95	57 180 0.68 0.43-1.10	66 184 0.95 0.61-1.48	1.01 0.98-1.03
			For por		only - http://b	mionon hmi	com/site/	about/guidal	inas vhtml	
			For pee	i leview	only - http://b	mjopen.bmj.	com/site/	about/guidel	mes.xntmi	
by copyright.	Protected	.124 by guest.	V on April 19, 2(moɔ.įmd.ne	om http://bmjope	Downloaded fro	iary 2017.	2833 on 9 Jan	10-810S-n9qojn	10.1136/br

)	Table IV: Association between head and neck cancer and exclusive exposure to combinations of chlorinated
- 3	solvents

4		C	Controls	OR [#]	05% 0
5 6		Cases (n=284)	(n=767)	UK	95% CI
7	Never exposed to TRI, PER or MC	246	693	1	
1	TRI only	20	32	1.81	0.81 to 4.04
8	PER only	0	3	-	-
9	TRI and PER	9	7	4.47	1.27 to 15.8
10	MC only	5	8	0.50	0.11 to 2.18
-	TRI and MC	8	18	1.66	0.58 to 4.77
11	TRI and PER and MC	1	3	2.16	0.19 to 24.1
12	TRI: trichloroethylene, PER: perchloroe	thylene, MC:	methylene chl	oride	
13	# OR adjusted for age at interview, dep	partment, alco	hol and tobac	co consump	tion.

OR adjusted for age at interview, department, alcohol and tobacco consumption.

Table V: Association between head and neck cancer sites and ever exposure to selected solvents


									1.1				
Ever exposure to	Controls	Cases	Oral ca OR [#]	CI 95%	Cases	Oropha OR [#]	CI 95%	Cases	Hypoph OR [#]	arynx CI 95%	Cases	Lary OR [#]	nx CI 95%
Methylene chloride	30	5	1.34	0.44 to 4.13	2	0.42	0.09 to 2.02	2	1.23	0.21 to 7.18	4	2.0	0.56 to 7.20
Trichloroethylene Perchloroethylene	60 13	12 1	2.12 0.98	0.97 to 4.60 0.11 to 8.47	13 5	1.66 3.43	0.78 to 3.54 1.01 to 11.8	3 0	2.45	0.57 to 10.5 -	10 4	3.80 7.95	1.55 to 9.32 1.92 to 32.9
Special petroleum product Diesel	54 26	10 2	1.79 0.88	0.78 to 4.09	7	0.87	0.35 to 2.17 0.60 to 6.03	2	1.05 3.60	0.19 to 5.78 0.55 to 23.4	7	2.24	0.82 to 6.09 0.66 to 9.53
Benzene	50	2	0.88	0.18 to 4.32 0.76 to 4.22	5 9	1.39	0.60 to 6.03 0.58 to 3.31	2	3.60 0.97	0.55 to 23.4 0.17 to 5.43	4 6	2.51	0.66 to 9.53 0.72 to 5.97
White-spirits Diethyl ether	247 88	32 10	1.54 0.91	0.90 to 2.66 0.41 to 2.06	21 8	0.54 0.51	0.30 to 0.95 0.22 to 1.20	10 3	1.67 0.74	0.65 to 4.29 0.18 to 3.05	20 2	1.70 0.30	0.86 to 3.37 0.07 to 1.40
Ketones Alcohols	83 365	13 41	1.58 1.02	0.77 to 3.25 0.61 to 1.73	14 40	1.24 0.59	0.62 to 2.48 0.36 to 0.97	5 15	1.93 1.43	0.59 to 6.26 0.57 to 3.56	11 22	2.66 0.89	0.82 to 6.09 0.66 to 9.53 0.72 to 5.97 0.86 to 3.37 0.07 to 1.40 1.17 to 6.07 0.46 to 1.75
# OR adjusted for age at		departm	ent, alc	ohol and toba	acco con	sumptio	on.						


 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 33 of 42

SUPPLEMENTARY MATERIALS


Supplementary - Figures 1





Page 35 of 42

Supplementary - Figures 2



For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Table S-I: Categories of exposure indices for solvents

f exposure indices	BMJ Op	ben	/bmjopen-2016-012833
	Probability of exposure	Intensity of exposure	لی Frequency o
	Probability of exposure	intensity of exposure	
Chloroform		not exposed; very low; low; medium;	
Carbon tetrachloride	_	high	January <1%; 1–10%/1–20%; 21–30%;;
Methylene chloride	<1%; 1–10%; 11–20%; 21–30%;; up to 91–100%		201 to 91–100%
Trichloroethylene	_	<5; 5–25; 26–50; 51–100; >100 ppm	. •
Perchloroethylene			Downloaded
Motors gasoline	6		oac
Special petroleum product		not exposed; low; medium; high	ded fr
Diesel	<1%; 1–10%; 11–50%; 50–90%; >90%		<0.5%; 0.5–5 3 ; 5–30%; 30–70%; >
Benzene		<0.1; 0.1–1; 1–5; 5–15; >15 ppm	http://bmjopen.b
White-spirits		<1 ; 1–20 ; 20–50 ; >50 ppm	- /bmjc
Ethylene glycol			per
Tetrahydrofurane	-	not exposed; low; medium; high	<1%; 1–10%; 11–20%; 21–30%;;
Diethyl ether	<1%; 1–10%; 11–20%; 21–30%;; up to 91–100%	not exposed; very low; low; medium;	to 91–100%
Ketones	1		
Alcohols	-	high	on April

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

19, 2024 by guest. Protected by copyright.

/bmjopen-2016-012833

1	
2	
2	
4	
5	
6	
7	
8	
g	
3 4 5 6 7 8 9 10	
11	
12	
13	
14	
15	
16	
17	
11 12 13 14 15 16 17 18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	

Table S-II: Associat	ion between head a	and neck cancer site an	d exposure to chlorinated solvents
----------------------	--------------------	-------------------------	------------------------------------

Controls Cases OR* Cl 95% p Cases OR* Cases OR* Cases OR* Cases OR*				0.	al cavity			0.50	nharuny			Hyp	onbaruny				Larynx	
Methylene chloride Veryer exposed 30 5 1.34 0.44 to 4.13 0.60 2 0.42 0.09 to 2.02 0.28 2 1.28 0.21 to 7.18 0.81 4 2.0 9 56 to 7.0 0.28 Cumulative Exposure Index - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 3 3.12 0.16 to 4.05 0.78 1 0.32 0.04 to 2.75 0.30 1 1.11 0.10 to 12.0 0.93 3 2.55 F5 to 9.32 0.003 - - - - 1 1.52 F5 to 9.10 0.22 10 3.40 1.3	Co	ntrols (Cases		CI 95%	р	Cases			р	Cases			р	Cases	OR [#]	CI 95%	р
c-median 15 2 1.39 0.27 to 7.16 0.69 2 0.92 0.17 to 4.94 0.92 - - - - 3 3.12 \$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$	Methylene chloride			•				•				•				•		
c-median 15 2 1.39 0.27 to 7.16 0.69 2 0.92 0.17 to 4.94 0.92 - - - - 3 3.12 \$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$	Ever exposed 3	30	5	1.34	0.44 to 4.13	0.60	2	0.42	0.09 to 2.02	0.28	2	1.23	0.21 to 7.18	0.81	4	2.0	a .56 to 7.20	0.28
≥ median 15 3 1.30 0.29 to 5.90 0.73 - - - 2 1.78 0.24 to 13.5 0.57 1 0.95 2.10 to 9.29 0.96 Duration of exposure - 2 1.78 0.24 to 13.5 0.57 1 0.95 2.10 to 9.29 0.96 ≥ 10 years 9 3 2.52 0.52 to 12.3 0.25 1 0.64 0.06 to 6.36 0.70 1 1.53 0.12 to 19.6 0.74 1 1.52 7.14 to 16.7 0.73 0.25 1 0.64 0.06 to 6.36 0.70 1 1.53 0.12 to 19.6 0.74 1 1.52 7.14 to 16.7 0.73 0.25 0.003 1 1.11 0.10 to 12.0 0.93 3 2.05 0.57 to 10.5 0.22 10 3.0 0.25 0.003 0.11 to 16.7 0.73 0.04 4 0.97 0.27 to 3.42 0.18 3 2.45 0.57 to 10.5 0.22 10 3.0 3.4 to 13.3 0.013 3.4 to 13.3 0.013 3.4 to 13.3 0.11 0.14 0.25																	лг	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $									0.17 to 4.94			-	-	-			20 .65 to 14.9	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		15	3	1.30	0.29 10 5.90	0.73	-	-	-	-	2	1.70	0.24 10 13.5	0.57	1	0.95	-	0.96
≥ 10 years 9 3 2.52 0.52 to 12.3 0.25 1 0.64 0.06 to 6.36 0.70 1 1.53 0.12 to 19.6 0.74 1 1.52 14 to 16.7 0.73 ichloroethylene 60 12 2.12 0.97 to 4.60 0.058 13 1.66 0.78 to 3.54 0.18 3 2.45 0.57 to 10.5 0.22 10 3.80 55 to 9.32 0.003 × median 30 4 1.38 0.42 to 4.57 0.59 9 2.30 0.93 to 5.71 0.07 1 1.22 0.12 to 12.1 0.86 6 4.22 3.4 to 13.3 0.013 ≥ median 30 8 2.73 1.02 to 7.30 0.04 4 0.97 0.27 to 3.42 0.96 2 4.13 0.72 to 2.37 0.11 4 3.25 7.92 to 13.4 0.67 7.92 to 13.4 0.92 to 13.4 0.067 7.92 to 32.9 0.11 0.62 to 3.49 0.37 3 2.31 0.52 to 10.3 0.27 8 3.47 2.8 to 9.41 0.014 2.10 years 13 1 0.98		21	2	0.79	0.16 to 4.05	0.78	1	0.32	0.04 to 2.75	0.30	1	1 1 1	0 10 to 12 0	0.93	3	2.35	0 54 to 10 3	0.25
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $																	0.14 to 16.7	
mulative Exposure Index																	.7	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		60	12	2.12	0.97 to 4.60	0.058	13	1.66	0.78 to 3.54	0.18	3	2.45	0.57 to 10.5	0.22	10	3.80	1.55 to 9.32	0.003
≥ median 30 8 2.73 1.02 to 7.30 0.04 4 0.97 0.27 to 3.42 0.96 2 4.13 0.72 to 23.7 0.11 4 3.25 7.92 to 11.4 0.067 Duration of exposure <10 years																	N	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $																	3.34 to 13.3	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		30	8	2.73	1.02 to 7.30	0.04	4	0.97	0.27 to 3.42	0.96	2	4.13	0.72 to 23.7	0.11	4	3.25	₹ ^{.92} to 11.4	0.067
≥ 10 years 13 6 6.84 2.11 to 22.1 0.001 4 2.54 0.63 to 10.3 0.19 0 2 4.73 6 86 to 26.0 0.074 erchloroethylene ver exposed 13 1 0.98 0.11 to 8.47 0.98 5 3.43 1.01 to 11.8 0.05 0 4 7.95 9.92 to 32.9 0.004 umulative Exposure Index < median 6 0 0.99 2 2.59 0.22 to 27 0.36 0 4 15.8 3.19 to 77.8 0.000 ≥ median 6 0 0.99 2 2.59 0.32 to 27.7 0.36 0 0 - 6 0		17	6	1 16	0 42 to 3 22	0.78	0	1 / 9	0.62 to 3.40	0.37	3	2.21	0.52 to 10.3	0.27	0	3 47	Q 28 to 0.41	0.014
terchloroethylene ver exposed 13 1 0.98 0.11 to 8.47 0.98 5 3.43 1.01 to 11.8 0.05 0 - - 4 7.95 9.92 to 32.9 0.004 variable ver exposed 13 1 0.98 0.11 to 8.47 0.98 5 3.43 1.01 to 11.8 0.05 0 - - 4 7.95 9.92 to 32.9 0.004 variable ver exposed 7 1 1.59 0.17 to 14.7 0.68 3 3.76 0.75 to 18.9 0.11 0 - - 4 15.8 3.19 to 77.8 0.000 ≥ median 6 0 - - 0.99 2 2.59 0.32 to 20.7 0.36 0 - - 0 - - 0 - - - 0 - - - 0 - - - 0 - - - 0 - - - 0 - - - 0 - - 0 - - 0 - -												-	-	-			0 86 to 26 0	
rer exposed 13 1 0.98 0.11 to 8.47 0.98 5 3.43 1.01 to 11.8 0.05 0 - - 4 7.95 G.92 to 32.9 0.004 Imulative Exposure Index 7 1 1.59 0.17 to 14.7 0.68 3 3.76 0.75 to 18.9 0.11 0 - - 4 7.95 G.92 to 32.9 0.004 <median< td=""> 6 0 - - 0.99 2 2.59 0.32 to 20.7 0.36 0 - - 4 15.8 3.19 to 77.8 0.000 ≥ median 6 0 - - 0.99 2 2.59 0.32 to 20.7 0.36 0 - - 0 - - - 0 - - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 <</median<>		10	Ŭ	0.04	2.111 to 22.11	0.001		2.04	0.00 10 10.0	0.10	0				2	4.70		0.014
Jimulative Exposure Index <td></td> <td>13</td> <td>1</td> <td>0.98</td> <td>0.11 to 8.47</td> <td>0.98</td> <td>5</td> <td>3.43</td> <td>1.01 to 11.8</td> <td>0.05</td> <td>0</td> <td>-</td> <td>-</td> <td>-</td> <td>4</td> <td>7.95</td> <td>a.92 to 32.9</td> <td>0.004</td>		13	1	0.98	0.11 to 8.47	0.98	5	3.43	1.01 to 11.8	0.05	0	-	-	-	4	7.95	a.92 to 32.9	0.004
< median 7 1 1.59 0.17 to 14.7 0.68 3 3.76 0.75 to 18.9 0.11 0.11 0 4 15.8 3.19 to 77.8 0.000 ≥ nedian 6 0 0.99 2 2.59 0.32 to 20.7 0.36 0 4 15.8 3.19 to 77.8 0.000 0 4 15.8 3.19 to 77.8 0.000 0 4 15.8 3.19 to 77.8 0.000 0 0 4 3.55 0.80 to 15.7 0.09 0 4 9.0 0 0 <p< td=""><td></td><td></td><td></td><td>0.00</td><td>0</td><td>0.00</td><td></td><td></td><td></td><td>0.00</td><td></td><td></td><td></td><td></td><td></td><td></td><td>B</td><td></td></p<>				0.00	0	0.00				0.00							B	
≥ median 6 0 - 0.99 2 2.59 0.32 to 20.7 0.36 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - 0 - - <t< td=""><td>< median</td><td></td><td></td><td>1.59</td><td>0.17 to 14.7</td><td></td><td></td><td></td><td></td><td></td><td></td><td>-</td><td>-</td><td>-</td><td></td><td>15.8</td><td>3.19 to 77.8</td><td>0.0007</td></t<>	< median			1.59	0.17 to 14.7							-	-	-		15.8	3 .19 to 77.8	0.0007
< 10 years 9 0 0.99 4 3.55 0.80 to 15.7 0.09 0 4 9.96 304 to 48.5 0.004 ≥ 10 years 4 1 9.50 0.89 to 101 0.06 1 3.22 0.33 to 31.5 0.31 0 0 0 -		6	0	-	-	0.99	2	2.59	0.32 to 20.7	0.36	0	-	-	-	0	-	ŧ	-
2 10 years 4 1 9.50 0.89 to 101 0.06 1 3.22 0.33 to 31.5 0.31 0 0 - 2 -																0.00		0.004
COR adjusted for age at interview, department, alcohol and tobacco consumption.				-	-				0.80 to 15.7	0.09	0	-	-	-	4	9.96	2.04 to 48.5	0.004
0																	April 19, 2024 t	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1
2
3
4
5
0
6
7
8
õ
9
10
11
12
12
13
14
15
16
17
40
18
19
2 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 10 112 3 4 5 6 7 8 9 30 3 1 2 2 3 4 5 6 7 8 9 3 1 2 2 3 4 5 6 7 8 9 3 1 2 2 3 4 5 6 7 8 9 3 1 2 2 3 4 5 6 7 8 9 3 1 2 2 3 4 5 6 7 8 9 3 3 1 2 3 3 4 5 6 7 8 9 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
21
22
22
23
24
25
26
20
21
28
29
30
21
31
32
33
34
35
00
36
37
38
39
40
41
42
43
44
45
46
47

1

Table S-III: Association between head and neck cancer site and exposure to petroleum solvents

								В	MJ O	pen					/bmjopen-2016-012833		
Table S-III: Asso	ciation	betwe		ral cavity	neck	cance		pharynx	osure	e to po		eum solv	ents			Larynx	
Special petroleum product	Controls	Cases	OR [#]	CI 95%	р	Cases	OR [#]	CI 95%	р	Cases	OR [#]	CI 95%	р	Cases		CI 95%	р
Ever exposed	54	10	1.79	0.78 to 4.09	0.17	7	0.87	0.35 to 2.17	0.76	2	1.05	0.19 to 5.78	0.95	7	2.24n	0.82 to 6.09	0.11
Cumulative Exposure Index < median	27	7	1.86	0.66 to 5.25	0.24	5	0.86	0.28 to 2.63	0.79	2	1.43	0.24 to 8.63	0.69	7	3.12ary	1.04 to 9.33	0.042
≥ median	27	3	1.81	0.50 to 6.59	0.37	2	0.96	0.20 to 4.57	0.95	0	-	-	-	0	- 7	-	-
Duration of exposure < 10 years	30	5	1.30	0.43 to 3.97	0.64	6	1.12	0.39 to 3.18	0.83	1	0.79	0.08 to 7.41	0.83	7	3.31 - -	1.12 to 9.74	0.030
≥ 10 years	24	5	2.75	0.85 to 8.85	0.091	1	0.39	0.05 to 3.19	0.38	1	1.55	0.13 to 19.0	0.73	0	- 1	-	-
Gasoil						_									·		
Ever exposed	26	2	0.88	0.18 to 4.32	0.87	5	1.90	0.60 to 6.03	0.27	2	3.60	0.55 to 23.4	0.18	4	2.51 1.62 3.60	0.66 to 9.53	0.17
Cumulative Exposure Index < median	12	0	-		0.99	3	1.81	0.38 to 8.53	0.45	1	3.24	0.24 to 44.3	0.37	2	1.6Ž	0.25 to 10.6	0.61
≥ median	14	2	1.91	0.37 to 9.78	0.44	2	1.80	0.33 to 9.88	0.49	1	3.57	0.27 to 47.1	0.33	2	3.60	0.62 to 20.7	0.15
Duration of exposure	10	0	4.00		0.57		0.00	0.004 445	0.40		0.00	0.004	0.00		4.42ed	4.04 / 10 -	0.047
< 10 years ≥ 10 years	16 10	2 0	1.62	0.30 to 8.65	0.57 0.99	4	3.02 0.62	0.80 to 11.5 0.06 to 6.36	0.10 0.68	1 1	3.38 4.87	0.28 to 41.1 0.33 to 71.7	0.33 0.24	4 0	4.4.2	1.04 to 18.8	0.045
Benzene	10	0			0.00		0.02	5.00 10 0.00	0.00	1	4.07	5.00 10 7 1.7	0.27	0	<u>c</u>		
Ever exposed	50	9	1.79	0.76 to 4.22	0.18	9	1.39	0.58 to 3.31	0.45	2	0.97	0.17 to 5.43	0.97	6	2.07pm	0.72 to 5.97	0.17
Cumulative Exposure Index	05	0	1.00	0.00 (- 5.50	0.00		4.17	0 10 10 0 10	0.77		0.70	0.001-7.70	0.00	-		0.75 10.0.70	0.40
< median ≥ median	25 25	6 3	1.86 1.62	0.63 to 5.52 0.42 to 6.22	0.26 0.48	6 3	1.17 2.06	0.40 to 3.43 0.53 to 8.01	0.77 0.29	1 1	0.78 1.21	0.08 to 7.72 0.10 to 14.8	0.82 0.88	5 1	2.57	0.75 to 8.79 0.09 to 8.79	0.13 0.92
Duration of exposure	20	0		0.12 10 0.22	0.10	0	2.00		0.20	1		0.10 10 1110	0.00		<u>o</u>	0.00 10 0.10	0.02
< 10 years	35	5	1.47	0.51 to 4.29	0.48	8	1.72	0.67 to 4.42	0.25	1	0.87	0.09 to 8.12	0.90	6	3.03	1.02 to 9.18	0.050
≥ 10 years	15	4	2.32	0.57 to 9.48	0.24	1	0.56	0.06 to 5.07	0.60	1	0.93	0.06 to 13.6	0.95	0	- <u>3</u>	-	-
Vhite-spirits Ever exposed	247	32	1.54	0.90 to 2.66	0.12	21	0.54	0.30 to 0.95	0.03	10	1.67	0.65 to 4.29	0.28	20	3.030mjop 1.760	0.86 to 3.37	0.12
Cumulative Exposure Index		02		0.0010 2.00	0.12							0.00 10 1120	0.20	20		0.00 10 0.01	02
< median	117	12	1.20	0.56 to 2.54	0.64	10	0.53	0.25 to 1.15	0.10	8	2.75	0.91 to 8.32	0.074	10	1.76	0.75 to 4.17	0.19
≥ median Duration of exposure	129	20	1.75	0.91 to 3.37	0.09	11	0.51	0.23 to 1.09	0.08	2	0.52	0.10 to 2.71	0.43	10	1.76 b 1.70 m	0.71 to 4.06	0.23
< 10 years	152	14	0.97	0.48 to 1.96	0.93	11	0.41	0.20 to 0.85	0.02	9	2.02	0.70 to 5.84	0.19	14	1.68	0.77 to 3.64	0.19
≥ 10 years	94	18	2.51	1.25 to 5.02	0.009	10	0.75	0.33 to 1.69	0.48	1	0.47	0.05 to 4.23	0.50	6	1.732	0.62 to 4.83	0.29
															on April 19, 2024 by guest. Protected by copyright.		

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	Diethy Under Start <				Ora	al cavity			Or	opharynx			Hvi	opharynx			S I	arynx	
Diethy Unitary ethor Currulative Exposure Index - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - <th>Diethy Under Start <</th> <th></th> <th>Controls</th> <th>Cases</th> <th></th> <th></th> <th>р</th> <th>Cases</th> <th></th> <th></th> <th>р</th> <th>Cases</th> <th></th> <th></th> <th>р</th> <th>Cases</th> <th></th> <th></th> <th></th>	Diethy Under Start <		Controls	Cases			р	Cases			р	Cases			р	Cases			
≥ median 44 4 0.51 0.15 to 1.74 0.28 5 0.51 0.17 to 1.56 0.24 2 0.73 0.12 to 4.58 0.74 1 0.22 0.03 to 1.86 0 Duration of exposure <10 years 25 4 1.49 0.42 to 5.35 0.54 2 0.64 0.13 to 3.09 0.57 1 0.98 0.10 to 9.76 0.98 1 0.770 0.02 to 1.48 0.02 to 1.48 0.22 0.03 to 1.86 0.02 to 1.48 0.02 1.17 to 6.07 0.02 to 1.48 <td>$\begin{array}{c c c c c c c c c c c c c c c c c c c$</td> <td>Diethyl ether</td> <td></td>	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Diethyl ether																	
≥ median 44 4 0.51 0.15 to 1.74 0.28 5 0.51 0.17 to 1.56 0.24 2 0.73 0.12 to 4.58 0.74 1 0.22 0.03 to 1.86 0 Duration of exposure <10 years	$\begin{array}{c c c c c c c c c c c c c c c c c c c $		88	10	0.91	0.41 to 2.06	0.83	8	0.51	0.22 to 1.20	0.12	3	0.74	0.18 to 3.05	0.67	2	0.30	0.07 to 1.40	0
≥ median 44 4 0.51 0.15 to 1.74 0.28 5 0.51 0.17 to 1.56 0.24 2 0.73 0.12 to 4.58 0.74 1 0.22 0.03 to 1.86 0 Duration of exposure <10 years	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Cumulative Exposure Index															2		
≥ median 44 4 0.51 0.15 to 1.74 0.28 5 0.51 0.17 to 1.56 0.24 2 0.73 0.12 to 4.58 0.74 1 0.22 0.03 to 1.86 0 Duration of exposure <10 years	$\begin{array}{c c c c c c c c c c c c c c c c c c c $																0.43 0		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		44	4	0.51	0.15 to 1.74	0.28	5	0.51	0.17 to 1.56	0.24	2	0.73	0.12 to 4.58	0.74	1	0.21	0.03 to 1.86	(
≥ 10 years 63 6 0.71 0.26 to 1.95 0.50 6 0.46 0.18 to 1.24 0.12 2 0.65 0.12 to 3.64 0.62 1 0.18 0.02 to 1.48 0.02 0.03 7 1.46 0.02 to 1.48 0.02 0.11 0.03 7 3.460 0.03 0.03 7 3.460 0.06 0.06 to 6.98 0.01 0.05 0.48 0.55 4 0.04 to 6.98 0.01 0.05 0.45 10 3.340 0.06 to 6.98 0.01 0.02 1.17 to 6.95 0.45 10 3.340	≥ 10 years 63 6 0.71 0.26 to 1.95 0.50 6 0.46 0.18 to 1.24 0.12 2 0.65 0.12 to 3.64 0.62 1 0.18 0.02 to 1.48 0.02 0.03 7 1.46 0.02 to 1.48 0.02 0.11 0.03 7 3.460 0.03 0.03 7 3.460 0.06 0.06 to 6.98 0.01 0.05 0.48 0.55 4 0.04 to 6.98 0.01 0.05 0.45 10 3.340 0.06 to 6.98 0.01 0.02 1.17 to 6.95 0.45 10 3.340																N		
Ketones Ever exposed 83 13 1.58 0.77 to 3.25 0.22 14 1.24 0.62 to 2.48 0.54 5 1.93 0.59 to 6.26 0.27 11 2.660 1.17 to 6.07 0 \leq median 42 8 2.08 0.83 to 5.23 0.13 10 1.94 0.82 to 4.58 0.12 4 4.37 1.13 to 16.9 0.032 7 3.460 0.60 to 6.98 0 \geq median 41 5 1.17 0.40 to 3.42 0.77 4 0.65 0.21 to 2.07 0.47 1 0.51 0.05 to 4.87 0.55 4 2.04 0.60 to 6.98 0 0.51 0.51 0.51 0.54 0.55 4 2.04 0.60 to 6.95 0.45 10 3.346 1.38 to 8.10 0 0 0.23 to 3.20 0.81 2 2.46 0.37 to 16.4 0.35 1	Ketones Ever exposed 83 13 1.58 0.77 to 3.25 0.22 14 1.24 0.62 to 2.48 0.54 5 1.93 0.59 to 6.26 0.27 11 2.660 1.17 to 6.07 0 \leq median 42 8 2.08 0.83 to 5.23 0.13 10 1.94 0.82 to 4.58 0.12 4 4.37 1.13 to 16.9 0.032 7 3.460 0.60 to 6.98 0 \geq median 41 5 1.17 0.40 to 3.42 0.77 4 0.65 0.21 to 2.07 0.47 1 0.51 0.05 to 4.87 0.55 4 2.04 0.60 to 6.98 0 0.51 0.51 0.51 0.54 0.55 4 2.04 0.60 to 6.95 0.45 10 3.346 1.38 to 8.10 0 0 0.23 to 3.20 0.81 2 2.46 0.37 to 16.4 0.35 1																0.770		
Ketones Ever exposed 83 13 1.58 0.77 to 3.25 0.22 14 1.24 0.62 to 2.48 0.54 5 1.93 0.59 to 6.26 0.27 11 2.660 1.17 to 6.07 Cumulative Exposure Index 42 8 2.08 0.83 to 5.23 0.13 10 1.94 0.82 to 4.58 0.12 4 4.37 1.13 to 16.9 0.032 7 3.460 0.60 to 6.98 ≥ median 41 5 1.17 0.40 to 3.42 0.77 4 0.65 0.21 to 2.07 0.47 1 0.51 0.05 to 4.87 0.55 4 2.040 0.60 to 6.98 Duration of exposure 1.13 0.65 0.31 0.85 0.81 2 2.46 0.37 to 16.4 0.35 10 3.340 0.11 to 7.99 Alcoho 1.02 0.61 to 1.73 0.93 40 0.59 0.36 to 0.97 0.03 15 1.43 0.57 to 3.56 0.44 22 0.890 0.46 to 1.75 Cumulative Exposure Index	Ketones Ever exposed 83 13 1.58 0.77 to 3.25 0.22 14 1.24 0.62 to 2.48 0.54 5 1.93 0.59 to 6.26 0.27 11 2.660 1.17 to 6.07 Cumulative Exposure Index 42 8 2.08 0.83 to 5.23 0.13 10 1.94 0.82 to 4.58 0.12 4 4.37 1.13 to 16.9 0.032 7 3.460 0.60 to 6.98 ≥ median 41 5 1.17 0.40 to 3.42 0.77 4 0.65 0.21 to 2.07 0.47 1 0.51 0.05 to 4.87 0.55 4 2.040 0.60 to 6.98 Duration of exposure 1.13 0.65 0.31 0.85 0.81 2 2.46 0.37 to 16.4 0.35 10 3.340 0.11 to 7.99 Alcoho 1.02 0.61 to 1.73 0.93 40 0.59 0.36 to 0.97 0.03 15 1.43 0.57 to 3.56 0.44 22 0.890 0.46 to 1.75 Cumulative Exposure Index	≥ 10 years	63	6	0.71	0.26 to 1.95	0.50	6	0.46	0.18 to 1.24	0.12	2	0.65	0.12 to 3.64	0.62	1	0.18	0.02 to 1.48	
Duration of exposure < 10 years	Duration of exposure < 10 years	Ketones															• •		
Duration of exposure Allowers 55 8 1.35 0.56 to 3.26 0.50 11 1.43 0.65 to 3.15 0.38 3 1.70 0.42 to 6.95 0.45 10 3.340 1.38 to 8.10 ≥ 10 years 28 5 2.19 0.70 to 6.81 0.18 3 0.85 0.23 to 3.20 0.81 2 2.46 0.37 to 16.4 0.35 1 0.936 0.11 to 7.99 0.46 to 1.75 0.42 to 6.95 0.44 22 0.890 0.46 to 1.75	Duration of exposure and the posure and the posure <t< td=""><td>Ever exposed</td><td>83</td><td>13</td><td>1.58</td><td>0.77 to 3.25</td><td>0.22</td><td>14</td><td>1.24</td><td>0.62 to 2.48</td><td>0.54</td><td>5</td><td>1.93</td><td>0.59 to 6.26</td><td>0.27</td><td>11</td><td>2.66</td><td>1.17 to 6.07</td><td></td></t<>	Ever exposed	83	13	1.58	0.77 to 3.25	0.22	14	1.24	0.62 to 2.48	0.54	5	1.93	0.59 to 6.26	0.27	11	2.66	1.17 to 6.07	
Duration of exposure Allowers 55 8 1.35 0.56 to 3.26 0.50 11 1.43 0.65 to 3.15 0.38 3 1.70 0.42 to 6.95 0.45 10 3.340 1.38 to 8.10 ≥ 10 years 28 5 2.19 0.70 to 6.81 0.18 3 0.85 0.23 to 3.20 0.81 2 2.46 0.37 to 16.4 0.35 1 0.936 0.11 to 7.99 0.46 to 1.75 0.42 to 6.95 0.44 22 0.890 0.46 to 1.75	Duration of exposure and the posure and the posure <t< td=""><td>Cumulative Exposure Index</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Ş</td><td></td><td></td></t<>	Cumulative Exposure Index															Ş		
Duration of exposure Allowers 55 8 1.35 0.56 to 3.26 0.50 11 1.43 0.65 to 3.15 0.38 3 1.70 0.42 to 6.95 0.45 10 3.340 1.38 to 8.10 ≥ 10 years 28 5 2.19 0.70 to 6.81 0.18 3 0.85 0.23 to 3.20 0.81 2 2.46 0.37 to 16.4 0.35 1 0.936 0.11 to 7.99 0.46 to 1.75 0.42 to 6.95 0.44 22 0.890 0.46 to 1.75	Duration of exposure and the posure and the posure <t< td=""><td>< median</td><td>42</td><td>8</td><td>2.08</td><td>0.83 to 5.23</td><td>0.13</td><td>10</td><td>1.94</td><td>0.82 to 4.58</td><td>0.12</td><td>4</td><td>4.37</td><td>1.13 to 16.9</td><td>0.032</td><td>7</td><td>3.46</td><td>1.24 to 9.65</td><td>(</td></t<>	< median	42	8	2.08	0.83 to 5.23	0.13	10	1.94	0.82 to 4.58	0.12	4	4.37	1.13 to 16.9	0.032	7	3.46	1.24 to 9.65	(
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	≥ median	41	5	1.17	0.40 to 3.42	0.77	4	0.65	0.21 to 2.07	0.47	1	0.51	0.05 to 4.87	0.55	4	2.04	0.60 to 6.98	(
Alcohols Ever exposed 365 41 1.02 0.61 to 1.73 0.93 40 0.59 0.36 to 0.97 0.03 15 1.43 0.57 to 3.56 0.44 22 0.89 0.46 to 1.75 0.46 to 1.75 Cumulative Exposure Index	Alcohols Ever exposed 365 41 1.02 0.61 to 1.73 0.93 40 0.59 0.36 to 0.97 0.03 15 1.43 0.57 to 3.56 0.44 22 0.89 0.46 to 1.75 0.46 to 1.75 Cumulative Exposure Index	Duration of exposure															ä		
Alcohols Ever exposed 365 41 1.02 0.61 to 1.73 0.93 40 0.59 0.36 to 0.97 0.03 15 1.43 0.57 to 3.56 0.44 22 0.89 0.46 to 1.75 0.46 to 1.75 Cumulative Exposure Index	Alcohols Ever exposed 365 41 1.02 0.61 to 1.73 0.93 40 0.59 0.36 to 0.97 0.03 15 1.43 0.57 to 3.56 0.44 22 0.89 0.46 to 1.75 0.46 to 1.75 Cumulative Exposure Index	< 10 years	55	8	1.35	0.56 to 3.26	0.50	11	1.43	0.65 to 3.15	0.38	3	1.70	0.42 to 6.95	0.45	10	3.34	1.38 to 8.10	(
Alcohols Ever exposed 365 41 1.02 0.61 to 1.73 0.93 40 0.59 0.36 to 0.97 0.03 15 1.43 0.57 to 3.56 0.44 22 0.89 0.46 to 1.75 0.46 to 1.75 Cumulative Exposure Index	Alcohols Ever exposed 365 41 1.02 0.61 to 1.73 0.93 40 0.59 0.36 to 0.97 0.03 15 1.43 0.57 to 3.56 0.44 22 0.89 0.46 to 1.75 0.46 to 1.75 Cumulative Exposure Index	≥ 10 years	28	5	2.19	0.70 to 6.81	0.18	3	0.85	0.23 to 3.20	0.81	2	2.46	0.37 to 16.4	0.35	1	0.930	0.11 to 7.99	
Ever exposed 365 41 1.02 0.61 to 1.73 0.93 40 0.59 0.36 to 0.97 0.03 15 1.43 0.57 to 3.56 0.44 22 0.890 0.46 to 1.75 0.46 to 1.75 Cumulative Exposure Index 180 17 0.80 0.41 to 1.58 0.52 18 0.4 0.25 to 0.91 0.02 11 1.86 0.67 to 5.16 0.23 11 0.77 to 3.46 to 1.77 0.34 to 1.77 0.45 to 2.37 0.45 to 2.31 0.45 to 2.37 0.45 to 2.45	Ever exposed 365 41 1.02 0.61 to 1.73 0.93 40 0.59 0.36 to 0.97 0.03 15 1.43 0.57 to 3.56 0.44 22 0.890 0.46 to 1.75 0.46 to 1.75 Cumulative Exposure Index 180 17 0.80 0.41 to 1.58 0.52 18 0.4 0.25 to 0.91 0.02 11 1.86 0.67 to 5.16 0.23 11 0.77 m 0.34 to 1.77 0.45 to 2.37 0.45 to																<u>4</u>		
< median 180 17 0.80 0.41 to 1.58 0.52 18 0.4 0.25 to 0.91 0.02 11 1.86 0.67 to 5.16 0.23 11 0.77 → 0.34 to 1.77 ≥ median 184 24 1.22 0.66 to 2.27 0.53 22 0.68 0.37 to 1.25 0.21 4 0.73 0.20 to 2.70 0.63 11 1.03 + 0.45 to 2.37 0.45 to 2.37 <td< td=""><td>< median 180 17 0.80 0.41 to 1.58 0.52 18 0.4 0.25 to 0.91 0.02 11 1.86 0.67 to 5.16 0.23 11 0.77 → 0.34 to 1.77 ≥ median 184 24 1.22 0.66 to 2.27 0.53 22 0.68 0.37 to 1.25 0.21 4 0.73 0.20 to 2.70 0.63 11 1.03 + 0.45 to 2.37 <td< td=""><td></td><td>365</td><td>41</td><td>1.02</td><td>0.61 to 1.73</td><td>0.93</td><td>40</td><td>0.59</td><td>0.36 to 0.97</td><td>0.03</td><td>15</td><td>1.43</td><td>0.57 to 3.56</td><td>0.44</td><td>22</td><td>0.89</td><td>0.46 to 1.75</td><td></td></td<></td></td<>	< median 180 17 0.80 0.41 to 1.58 0.52 18 0.4 0.25 to 0.91 0.02 11 1.86 0.67 to 5.16 0.23 11 0.77 → 0.34 to 1.77 ≥ median 184 24 1.22 0.66 to 2.27 0.53 22 0.68 0.37 to 1.25 0.21 4 0.73 0.20 to 2.70 0.63 11 1.03 + 0.45 to 2.37 0.45 to 2.37 <td< td=""><td></td><td>365</td><td>41</td><td>1.02</td><td>0.61 to 1.73</td><td>0.93</td><td>40</td><td>0.59</td><td>0.36 to 0.97</td><td>0.03</td><td>15</td><td>1.43</td><td>0.57 to 3.56</td><td>0.44</td><td>22</td><td>0.89</td><td>0.46 to 1.75</td><td></td></td<>		365	41	1.02	0.61 to 1.73	0.93	40	0.59	0.36 to 0.97	0.03	15	1.43	0.57 to 3.56	0.44	22	0.89	0.46 to 1.75	
< median 180 17 0.80 0.41 to 1.58 0.52 18 0.4 0.25 to 0.91 0.02 11 1.86 0.67 to 5.16 0.23 11 0.77 → 0.34 to 1.77 ≥ median 184 24 1.22 0.66 to 2.27 0.53 22 0.68 0.37 to 1.25 0.21 4 0.73 0.20 to 2.70 0.63 11 1.03 + 0.45 to 2.37 0.45 to 2.37 <td< td=""><td>< median 180 17 0.80 0.41 to 1.58 0.52 18 0.4 0.25 to 0.91 0.02 11 1.86 0.67 to 5.16 0.23 11 0.77 → 0.34 to 1.77 ≥ median 184 24 1.22 0.66 to 2.27 0.53 22 0.68 0.37 to 1.25 0.21 4 0.73 0.20 to 2.70 0.63 11 1.035 0.45 to 2.37 0.45 to 2.37 Duration of exposure 0.96 0.55 to 2.01 0.87 20 0.62 0.34 to 1.15 0.12 10 1.91 0.68 to 5.38 0.22 15 1.24 0.58 to 2.64 0.58 to 2.64 ≥ 10 years 196 21 0.96 0.51 to 1.83 0.90 20 0.54 0.29 to 1.01 0.055 5 0.82 0.23 to 2.87 0.75 7 0.577 0.22 to 1.46</td><td></td><td>000</td><td></td><td></td><td>2.01.10 1.10</td><td>0.00</td><td></td><td></td><td></td><td></td><td></td><td></td><td>2.07 10 0.00</td><td>0</td><td></td><td>Ť</td><td>5110 10 1110</td><td></td></td<>	< median 180 17 0.80 0.41 to 1.58 0.52 18 0.4 0.25 to 0.91 0.02 11 1.86 0.67 to 5.16 0.23 11 0.77 → 0.34 to 1.77 ≥ median 184 24 1.22 0.66 to 2.27 0.53 22 0.68 0.37 to 1.25 0.21 4 0.73 0.20 to 2.70 0.63 11 1.035 0.45 to 2.37 0.45 to 2.37 Duration of exposure 0.96 0.55 to 2.01 0.87 20 0.62 0.34 to 1.15 0.12 10 1.91 0.68 to 5.38 0.22 15 1.24 0.58 to 2.64 0.58 to 2.64 ≥ 10 years 196 21 0.96 0.51 to 1.83 0.90 20 0.54 0.29 to 1.01 0.055 5 0.82 0.23 to 2.87 0.75 7 0.577 0.22 to 1.46		000			2.01.10 1.10	0.00							2.07 10 0.00	0		Ť	5110 10 1110	
≥ median 184 24 1.22 0.66 to 2.27 0.53 22 0.68 0.37 to 1.25 0.21 4 0.73 0.20 to 2.70 0.63 11 1.03 0.45 to 2.37 Duration of exposure <td< td=""><td>≥ median 184 24 1.22 0.66 to 2.27 0.53 22 0.68 0.37 to 1.25 0.21 4 0.73 0.20 to 2.70 0.63 11 1.03 0.45 to 2.37 Duration of exposure <td< td=""><td></td><td>180</td><td>17</td><td>0.80</td><td>0.41 to 1.58</td><td>0.52</td><td>18</td><td>0.4</td><td>0.25 to 0.91</td><td>0.02</td><td>11</td><td>1.86</td><td>0.67 to 5.16</td><td>0.23</td><td>11</td><td>0.77</td><td>0.34 to 1.77</td><td></td></td<></td></td<>	≥ median 184 24 1.22 0.66 to 2.27 0.53 22 0.68 0.37 to 1.25 0.21 4 0.73 0.20 to 2.70 0.63 11 1.03 0.45 to 2.37 Duration of exposure <td< td=""><td></td><td>180</td><td>17</td><td>0.80</td><td>0.41 to 1.58</td><td>0.52</td><td>18</td><td>0.4</td><td>0.25 to 0.91</td><td>0.02</td><td>11</td><td>1.86</td><td>0.67 to 5.16</td><td>0.23</td><td>11</td><td>0.77</td><td>0.34 to 1.77</td><td></td></td<>		180	17	0.80	0.41 to 1.58	0.52	18	0.4	0.25 to 0.91	0.02	11	1.86	0.67 to 5.16	0.23	11	0.77	0.34 to 1.77	
Contained of exposure of e	Contained of exposure of e																1.03		
< 10 years 168 20 1.05 0.55 to 2.01 0.87 20 0.62 0.34 to 1.15 0.12 10 1.91 0.68 to 5.38 0.22 15 1.24 0.58 to 2.64 ≥ 10 years 196 21 0.96 0.51 to 1.83 0.90 20 0.54 0.29 to 1.01 0.055 5 0.82 0.23 to 2.87 0.75 7 0.57 0.22 to 1.46	< 10 years 168 20 1.05 0.55 to 2.01 0.87 20 0.62 0.34 to 1.15 0.12 10 1.91 0.68 to 5.38 0.22 15 1.24 0.58 to 2.64 ≥ 10 years 196 21 0.96 0.51 to 1.83 0.90 20 0.54 0.29 to 1.01 0.055 5 0.82 0.23 to 2.87 0.75 7 0.57 0.22 to 1.46					0.00 10 2.2.1	0.00		0.00	0.01 10 1.20			00	0.20 10 2.10	0.00		0	0.10 10 2.01	
≥ 10 years 196 21 0.96 0.51 to 1.83 0.90 20 0.54 0.29 to 1.01 0.055 5 0.82 0.23 to 2.87 0.75 7 0.576 0.22 to 1.46 # OR adjusted for age at interview, department, alcohol and tobacco consumption.	≥ 10 years 196 21 0.96 0.51 to 1.83 0.90 20 0.54 0.29 to 1.01 0.055 5 0.82 0.23 to 2.87 0.75 7 0.570 0.22 to 1.46 # OR adjusted for age at interview, department, alcohol and tobacco consumption.		168	20	1.05	0.55 to 2.01	0.87	20	0.62	0.34 to 1.15	0.12	10	1 91	0.68 to 5.38	0.22	15	1 24	0.58 to 2.64	
# OR adjusted for age at interview, department, alcohol and tobacco consumption.	# OR adjusted for age at interview, department, alcohol and tobacco consumption.																0.57		
	n April 1																		
19, 20,																	en.bmj.com/ on April 19, 20		
9, 2024 by	24 by																en.bmj.com/ on April 19, 2024 by		
9, 2024 by gue	24 by gue																njopen.bmj.com/ on April 19, 2024 by guest.		

ijopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

/bmjopen-2016-012833

1 2 3 4 5 6	ST
7 8 9	Tit
10 11 12 13	Int Ba
14 15 16	Ob
16 17	M
18	Stu
19 20	Set
21 22 23 24	Par
25 26 27	Va
28 29	Da
30 31	me
32 33	Bia
34	Stu
35 36	Qu
37 38 39 40	Sta
41 42 43 44	
45	Re
46 47 48 49	Par
50 51	
52 53 54 55	De

56 57

58

59

60

	Item No		Page in main
		Recommendation	doc
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was	3
		done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
· · · · · · · · · · · · · · · · · · ·	5	Suce specific objectives, meruding any prespectived hypotheses	U
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of	7
		recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment	7-8
		and control selection. Give the rationale for the choice of cases and controls	
		(b) For matched studies, give matching criteria and the number of controls per	-
		case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and	8-9
		effect modifiers. Give diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of methods of	9
measurement		assessment (measurement). Describe comparability of assessment methods if	
		there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	10
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,	10
		describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for	10-11
		confounding	
		(b) Describe any methods used to examine subgroups and interactions	10-11
		(c) Explain how missing data were addressed	
		(d) If applicable, explain how matching of cases and controls was addressed	
		(<u>e</u>) Describe any sensitivity analyses	11
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially	X
i articipants	15	eligible, examined for eligibility, confirmed eligible, included in the study,	Δ
		completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	X
Descriptions data	1.4*	(c) Consider use of a flow diagram	X
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social)	12 +
		and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	12 +
			Table 1
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure	Table I
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates	12-14 +

For peer review only - http://bmjopen!bmj.com/site/about/guidelines.xhtml

and their precision (eg, 95% confidence interval). Make clear which confounders	Tables
were adjusted for and why they were included	
(b) Report category boundaries when continuous variables were categorized	Tables
(c) If relevant, consider translating estimates of relative risk into absolute risk for	
a meaningful time period	
•	

BMJ Open: first published as 10.1136/bmjopen-2016-012833 on 9 January 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14 + Tables
			and
			Suppl.
			Mat
Discussion			
Key results	18	Summarise key results with reference to study objectives	16
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.	20-21
		Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations,	16-19
		multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	22
Other informati	ion		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable,	23
		for the original study on which the present article is based	

*Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

For peer review only - http://bmjopen?bmj.com/site/about/guidelines.xhtml